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INTRODUCTION: 
Diabetes Mellitus is a metabolic disorder primarily affecting the neurovascular 
system. Currently, it is a worldwide problem, becoming an impending epidemic in 
India. According to the WHO, the term diabetes mellitus describes a metabolic 
disorder of multiple aetiology characterized by chronic hyperglycemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from defects in 
insulin secretion, insulin action, or both.(1) 
The effects of diabetes mellitus include long-term micro and macro vascular 
complications. Diabetes and its complications together constitute an extensive 
burden on the health care system, especially in a developing country like India 
where resources for management are few. Therefore, optimal control of diabetes 
along with  early diagnosis and management of complications  is very important.  
Diabetic peripheral neuropathy, which is the most common complication, if not 
diagnosed and managed well, can lead to  foot ulcers, Charcot joint and ultimately 
loss of limb. All these contribute towards significant mortality, morbidity and 
economic burden. Early diagnosis gives the opportunity for the patient to optimize 
glycemic control and implement better foot care before the onset of significant 
morbidity. Hence it becomes essential to assess for these complications at routine 
intervals with appropriate screening tools.  
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A number of measuring tools are used for assessment of neuropathy ranging from 
different questionnaires, monofilament testing, biothesiometer and nerve 
conduction studies. Till date there is no consensus on the gold standard tool for 
assessment of neuropathy. In this study we try to compare the various screening 
tools used in diabetic peripheral neuropathy.   
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AIM& OBJECTIVES 
 
AIM: 
To study the usefulness of clinical testing as compared to Nerve conduction studies for 
the early detection of sensorimotor polyneuropathy in patients with Type 2 Diabetes 
Mellitus.  
OBJECTIVES: 
1. To study the occurrence of peripheral neuropathy in patients with 
diabetes mellitus  by using standard outpatient clinical tools and nerve 
conduction studies  
2. To compare the  results of  nerve conduction studies, Semmes Weinstein 
monofilament testing and vibration perception testing using 
biothesiometer with the results of MNSI  (Michigan Neuropathy 
Screening Instrument) in the detection of  diabetic sensorimotor 
polyneuropathy. 
3. To compare the results of biothesiometer testing with Nerve conduction 
studies in detection of diabetic sensorimotor polyneuropathy. 
4. To assess the usefulness of minimal F wave latency and sural radial 
amplitude ratio (SRAR) in early detection of diabetic polyneuropathy 
12 
 
5. To study the sensitivities and specificities of the various screening 
instruments used to detect diabetic peripheral neuropathy based on nerve 
conduction studies as the gold standard 
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REVIEW OF LITERATURE: 
Diabetes Mellitus is on the verge of becoming an epidemic in India, and  currently 
has the  highest number of cases. With increasing urbanization, prevalence of 
obesity and physical inactivity have gone up  and there is an increase in the 
number of people with diabetes. According to the 2014 data, there are 387 million 
people with diabetes in the world and it has been estimated that 592 million people 
will be affected by 2035.(2) According to the International Federation of Diabetes, 
India has the highest number of Diabetics in the world. According to the current 
statistics in India, the prevalence of Diabetes is 62 million, and 100 million people 
are estimated to suffer from Diabetes mellitus by the year 2030. (3) 
The true prevalence of diabetic neuropathy is not known. Various studies suggest 
the prevalence to vary from 10-90%.(4) This could be attributed to the fact that  
different screening tools are used for detecting diabetic neuropathy. The other 
significant factors contributing to this variation are the age of the patient and the 
time lapsed before diagnosis. A prospective study to detect the prevalence of 
diabetic neuropathy in newly diagnosed diabetics, in Northern India showed a 
prevalence of around 30%.(5,6) Another study done on 1629 diabetics in South 
India showed a similar prevalence of 26.1%.(7)This study aims to compare the 
results of various screening tests to detect peripheral neuropathy in patients with 
diabetes mellitus. 
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CLINICAL FEATURES AND COMPLICATIONS OF TYPE 2 DIABETES 
MELLITUS: 
Patients with Diabetes Mellitus may initially present with polydipsia, polyuria, 
blurring of vision, and weight loss. However, many a time, symptoms are not 
severe and the silent hyperglycemia may cause pathological functional changes 
before the diagnosis is made. Acute and Chronic complications may occur. The 
acute complications include ketoacidosis or a non-ketotic hyperosmolar state. The 
chronic complications include retinopathy, nephropathy, and neuropathy with risk 
of foot ulcers, amputation, Charcot joints, features of autonomic dysfunction, 
increased risk of cardiovascular, peripheral vascular and cerebrovascular 
disease.(1)14.3% of the diabetics have foot ulcers.(8) The incidence is higher in 
India than in the Western population and this could be attributed to various social 
and cultural practices of barefoot walking. Low socio-economic status and 
illiteracy leads to inappropriate usage of footwear and increasing incidence of foot 
ulceration(9). Foot ulcers precede over 85% of lower limb amputations. Diabetes 
is the major cause of non-traumatic amputation across the world, rates of which 
are 15 times higher as compared to amputation rate among non-diabetic 
population.(10) Another study showed that around 10.5% of diabetics underwent 
major amputations and the postoperative mortality was 14.7%. (11) 
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DIABETIC PERIPHERAL NEUROPATHY- DEFINITION AND TYPES: 
Diabetes mellitus is associated with various neuropathy syndromes that differ in 
their aetiology, natural history, and treatment. Diabetic neuropathy can be defined 
as the presence of symptoms and/or signs of peripheral nerve dysfunction in 
people with diabetes after the exclusion of other causes.(12) 
As with other complications of diabetes mellitus, the development of neuropathy 
correlates with age, anthropometric measures like height of the patient,  duration 
of diabetes and glycemic control. Neuropathy can be broadly divided into 
symmetric and asymmetric types, although a great deal of overlap exists between 
these categories. The pattern and the symptomatology depend on the type of nerve 
fibres involved. Figure 1 shows the different types of nerve fibres of the peripheral 
nervous system and outlines the symptoms attributed to each type of fibre.   
Symmetric neuropathies may present as small-fibre or large fibre involvement or 
autonomic dysfunction. Asymmetric Diabetic Neuropathy includes cranial 
neuropathies, limb mononeuropathies, radiculopathies, plexopathies, and diabetic 
amyotrophy.  
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The types of Diabetic neuropathy are outlined below: 
Rapidly reversible hyperglycaemic neuropathy: 
This is characterised by reversible distal sensory symptoms in patients with 
recently diagnosed diabetes or in those with a poor glycemic control. When they 
reach a euglycemic state, recovery tends to occur.  
 
Figure 1 - Simplified view of the peripheral nervous system 
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Diabetic Sensorimotor Polyneuropathy:  
Length-dependent sensorimotor polyneuropathy (DSPN) is the most common type 
of diabetic neuropathy accounting to around 80%(13). It can be found at the time 
of diagnosis of Type 2 diabetes itself. This type is predominantly distal and 
symmetric. It is a mixed neuropathy with small- and large-fibre, sensory, 
autonomic, and motor nerve involvement in various combinations, with sensory 
and autonomic symptoms more prominent than motor ones. Length dependent 
diabetic polyneuropathy usually starts at the feet and progresses proximally, and as 
it reaches the knee, symptoms would start in the distal aspects of the hand, 
progressing proximally in both upper and lower limbs. When it reaches the most 
proximal part of the lower limbs, it can progress to the anterior aspect of the trunk, 
involving the sensory component of the intercostal nerves. This indicates that the 
neuropathy is length dependent.  
Symptoms can range from being completely clinically silent to symptoms like 
pain, hyperesthesia, parasthesia, burning and tingling. They can also present with  
negative symptoms like and numbness, painless foot ulcers, subsequently leading 
to amputation. They may occasionally present with unsteadiness due to abnormal 
proprioception and decreased sensation. The clinically silent variety can be 
detected only by examination. 
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In Diabetes, there is a loss of both myelinated and unmyelinated nerve fibers. 
There can be an involvement of both small and large fibres. Small fibre 
neuropathy presents with reduced intra-epidermal nerve fibre density. The first 
modalities to be affected are pain and temperature.  Loss of large myelinated 
fibrescan cause disturbance of light touch, vibration and joint position sense. 
(Figure 1) Motor involvement occurs at a later stage, only when there is profuse 
sensory involvement, and is not quite common.  
Neuropathic pain can occur and is a disabling condition if present. It is more 
common in small fibre neuropathy with intra-epidermal nerve fibre loss.  Trophic 
changes can also occur in symmetric sensory polyneuropathy. They first present 
with callus formation or a painless phlyctenular lesion(14). This is followed by 
bullous lesions and plantar ulcers. The ulcers can progress and lead to an ankle 
joint arthropathy. However, ulceration and arthropathy are not only limited to 
diabetes. Any condition causing loss of sensation of the feet, like leprosy, 
meningomyelocoele, hereditary sensory and alcoholic sensory neuropathies can 
also result in arthropathy. 
Diabetic Autonomic Neuropathy: 
Autonomic dysfunction is one of the serious manifestations of neuropathy, which 
often co-exist with small fibre neuropathy. It has a significant negative impact on 
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survival.(12) It has a varied presentation including the gastrointestinal, 
cardiovascular and genito-urinary symptoms.  
Focal and Multifoal Neuropathies: 
Focal and multifocal neuropathies are much less common. They include 
entrapment neuropathies, mononeuropathies, cranial nerve neuropathies, proximal 
diabetic neuropathy of lower limbs and limb and truncal neuropathies.  
Mononeuropathies are usually of acute onset, involve the median nerve(5.8% of 
diabetic neuropathies), ulnar nerve(2.1%), radial nerve(0.6%) and common 
peroneal nerves(15). They are associated with pain, however have a self limiting 
course.  
Entrapment syndromes differ from mononeuropathies in that they have a gradual 
onset, are progressive and persist if intervention is not done. Carpel tunnel 
syndrome is a common entrapment neuropathy. A study done by Perkins et al 
showed that the prevalence of CTS was 2% in the reference population (without 
diabetes and without neuropathy), 14% in diabetics without polyneuropathy and 
30% in those with diabetic polyneuropathy. (16) 
Cranial neuropathies are extremely rare in diabetic patients. Occulomotor nerve 
palsy presents with severe eye pain and paresis of extra ocular muscles innervated 
by it, accompanied by ptosis. It usually . It usually spares the pupil as the 
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parasympathetic fibres are in the periphery and the vascular origin in diabetes  
leads to centrofascicular involvement.  
Diabetic Amyotrophy: This is usually seen in older patients and presents with 
unilateral or bilateral muscle weakness, severe pain and proximal atrophy of the 
thighs. It is thought to be due to immune mediated epineural microvasculitis, 
though the exact mechanism is not known.(12) 
Diabetic Truncal Radiculoneuropathy:Truncal neuropathies are predominantly 
unilateral, with an abrupt onset and pain and dysesthesias as main features. They 
can sometimes be bilateral and involve the lower thoracic and abdominal wall in a 
girdle like distribution. 
Acute Sensory Neuropathy: This is a distinctive variant of Diabetic peripheral 
neuropathy. This syndrome is also called Diabetic cachexia. Symptoms are 
usually severe pain, weight loss, cachexia, depression and sometimes erectile 
dysfunction in males. Clinical signs are rare with occasionally absent ankle reflex 
and allodynia. This can happen due to poor glycemic control or due to rapid 
improvement of glycaemia. The rapid changes in the blood glucose entry into the 
cells causing alterations in epineural blood flow, lead to ischemia(12). Pain fibres 
are predominantly involved. However the pathological basis of this condition is 
not yet determined, and immune mechanisms are likely(18). Natural history of the 
disease is resolution of symptoms in one year.   
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Insulin Neuritis: 
This is a rare entity and is seen after starting the patients on insulin therapy. 
Studies have said that insulin causes a reduction in endoneurial oxygen tension in 
normal nerves, however diabetic nerves are resistant to these changes. However, 
once the hyperglycemia is controlled, the nerves become sensitive to insulin and 
can lead to neuritis(19). This could be immune mediated as well.  
 
PATHOPHYSIOLOGY OF DIABETIC NEUROPATHY: 
Diabetes affects the autonomic and peripheral nervous systemleading to diabetic 
neuropathy, the most common complication during the course of disease leading 
to increased mortality and morbidity. Diabetic neuropathy is a heterogeneous 
condition in view of its varied presentation which can be focal, multifocal or 
diffuse, proximal or distal. Multiple metabolic components and ischemic changes 
are responsible for diabetic neuropathy, most important being the hyperglycemia. 
Other factors responsible for DN are dyslipidemia, impaired insulin signaling and 
various other metabolic alterations as a result of above factors. 
Hyperglycemia: Excess intracellular glucose influxvia different metabolic 
pathways leads to cell damage. Hyperglycaemia induces hypoxic environment and 
oxidative stress. These changes result in abnormal neuronal, axonal, and Schwann 
cell metabolism, which result in impaired axonal transport.Activation of protein 
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kinase C has been linked to vascular damage in DN.
 
Figure 2: Pathophysiology of Diabetic peripheral neuropathy 
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Excessive glycolysis may overload mitochondrial electron transport which 
generates ROS. Influx through polyglycol pathway leads to intracellular 
hyperosmolarity, resulting in reduced NADPH levels and increased oxidative 
stress (Figure 2).Activation of Polyol pathway in the nerve through enzyme aldose 
reductase leads to accumulation of sorbitol and fructose in the nerve and induces 
non‐enzymatic glycosylation of structural nerve proteins. Long term inflammatory 
signaling upregulates RAGE and activates NFkB. Increased glucose influx 
through the hexosamine pathway is associated with inflammatory injury. 
Dyslipidemia: Dyslipidemia is found in many of the patients with Type 2 
Diabetes and this also plays a role in the pathophysiology of diabetic neuropathy. 
Several underlying mechanisms have been identified. It has been observed in vitro 
that free fatty acids (FFAs) can directly cause injury to Schwann cells. They also 
have systemic effects such as promoting inflammatory cytokine release from 
adipocytes and macrophages. Plasma lipoproteins, particularly low-density 
lipoproteins (LDLs), can be modified by oxidation (oxLDL) and/or glycation, and 
these modified LDLs can bind to extracellular receptors (including the oxLDL 
receptor LOX153, Toll-like receptor 454 and RAGE47), triggering signaling 
cascades that activate NADPH oxidase and subsequently cause oxidative 
stress(Figure 2). Cholesterol may also be oxidized to oxysterols, which have a role 
in promoting apoptosis in neurons. 
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Impaired insulin signaling: 
Insulin has been shown to have neurotrophic effects, promoting neuronal growth 
and survival. Insulin deficiency in Type 1 Diabetes and insulin resistance in type 2 
diabetes cause a decrease in this neurotrophic signaling and probably contributes 
to the pathogenesis of diabetic neuropathy. As is seen in muscle and adipose 
tissue, in neurons also insulin resistance occurs by inhibition of the PI3K/Akt 
signaling pathway. Disruption of this pathway may also lead to mitochondrial 
dysfunction and oxidative stress, further promoting neuropathy. These 
mechanisms lead to multiple cellular disturbances, including mitochondrial 
dysfunction, endoplasmic reticulum (ER) stress, DNA damage and apoptosis.  
 
SCREENING TESTS FOR DIABETIC PERIPHERAL NEUROPATHY: 
Role of Michigan Neuropathy Screening Instrument: 
Michigan Neuropathy Screening Instrument is a clinical tool for screening diabetic 
peripheral neuropathy. It comprises two parts, a self administered questionnaire 
which can be totalled up to arrive at a history score and an examination part, 
which can be performed easily by General practitioners  and internists. It can be 
easily interpreted as well.  
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A study done by Ali Moghataderi et al had compared MNSI with NCS and 
obtained sensitivities and specificities for various cut offs. They observed that 
79% sensitivity at a cut off value of >/= 1.5 decreases to 35% when the cut off is 
increased to 3. However the specificity increased with increase in the cut off value 
of MNSI.  
It is a good screening tool, however, it is just a screening test and other methods 
are needed for confirming the diagnosis. (20)Another limitation of MNSI is its 
inadequacy for screening of the Autonomic nervous system.  
Role of Semmes Weinstein Monofilament: 
Back in the 1960s, a set of nylon filaments were first used by two 
neuropsychologists, Sidney Weinstein and Florence Semmes to assess the sensory 
loss in patients with penetrating brain injury. This came to be called Semmes 
Weinstein Monofilament. It had replaced the use of horse hair for sensory testing, 
overcoming a lot of the drawbacks of horse hair, one being absorption of 
humidity(21,22).  Semmes Weinstein monofilament is a controlled instrument for 
sensory testing due to the fact that the nylon bends when an intended force of 
application is delivered. The monofilament is available in different sizes, eg. a 
monofilament with 5.07 gauze size delivers a 10 gram force and buckles when the 
10 grams are delivered. This is called a 5.07/10 gram monofilament. 
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Semmes Weinstein monofilament is recommended as a screening tool for diabetic 
peripheral neuropathy by several guidelines. (23,24) It is a simple, inexpensive, 
easy to use and portable test and assesses loss of protective sensation.   
Not only is it considered an effective screening tool for the outpatient departments, 
but also, patients who are willing to learn, can be taught how to use it, as it would 
help in early diagnosis and would motivate them for better glycemic control(25).  
There is no standard method of application of monofilament. Some studies have 
recommended using it at one site (26) and others at several sites. There is 
difference in the interpretation of the test as well. A systematic review by Dros et 
al had included four studies in order to assess whether 10 gram monofilament was 
useful as a diagnostic test for peripheral neuropathy of any cause. The sensitivity 
of monofilament varied from 41 to 93% and the specificity varied from 68 to 
100%. These differences are also possibly due to differences in study populations, 
differences in the methods of application and interpretation. They concluded that 
despite the frequent use of monofilament for screening of diabetic peripheral 
neuropathy, little can be said about its diagnostic value due to lack of studies with 
a standard technique and proper methodology. It cannot be used as a single 
diagnostic test and needs to be coupled with other clinical testing, and when in 
doubt, nerve conduction studies need to be done to establish the diagnosis. (27) 
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The sensitivity and specificity has widely varied between the studies(28–32). The 
reason for this could be that different studies have compared the Monofilament 
testing to different gold standards. Some studies have taken clinical testing as gold 
standard, while others have taken biothesiometer or thermal testing as gold 
standards. Other reasons for this could be that the test was applied in different 
populations and the method of application was different with differences in the 
sites and number of sites of testing. Diabetes can affect sensory nerves differently 
in different regions of the foot, and variation could occur due to testing over 
calluses also. (21) 
Perkins et al compared the simple screening tests for peripheral neuropathy with 
the standard criteria of nerve conduction studies. The screening tools they used 
were Semmes Weinstein Monofilament, pin prick testing, vibration on-off method 
and vibration timed method (by a 128Hz tuning fork). Of the four sensory 
modalities, vibration testing by the on-off method had the highest positive 
likelihood ratio of 26.6 and a low negative likelihood ratio of 0.51. The specificity 
was 99% for five or more insensate responses. Both the10-g monofilament and 
superficial pain modalities had comparable likelihood ratios(10.2 and 9.2), but 
better sensitivity was observed with the 10-gmonofilament(40%) and better 
specificity was observed for superficial pain (97%), Semmes Weinstein 
monofilament, superficial pain sensation testing, and vibration testing by the on-
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off method each required less than 60 seconds to perform accurately. Vibration 
testing by the timed method took longer depending on the degree of normalcy.(33) 
Role of Biothesiometry in Diabetic Peripheral Neuropathy: 
Biothesiometer is a device that is used to measure accurately the threshold of 
perception of vibration sense. Tuning fork with a frequency of 128 Hz has been 
widely used as a screening tool for diabetic peripheral neuropathy. Biothesiometer 
works as an electrical tuning fork and helps detect large fibre neuropathy earlier. It 
has a vibrating probe, which is placed on the patient's foot. The vibration 
amplitude, measured in volts can be increased gradually by turning a dial. The 
patient is asked to indicate as soon as the vibration is felt. The value is then 
recorded. In this way, the biothesiometer helps to detect the severity of 
neuropathy.  
As in the case of any other device, biothesiometer also has its own limitations. 
There could be a confounding effect of the pressure applied on the vibrating probe, 
limb temperature, limb site, tactile surface of the skin, the understanding level of 
the patient and psychological factors. Despite all these disadvantages, it is 
considered as a good screening tool for diabetic neuropathy.  
There is a controversy about the sensitivity and specificity of biothesiometer, 
which exists because of the difference in the gold standard tool used to determine 
the sensitivity and specificity of biothesiometer. Young et al has shown that the 
29 
 
sensitivity is 80% and specificity is 98%. This was a one year follow up study to 
observe the development of ulcer based on the vibration proprioception threshold 
value.(34) In the study by Pourhamidi et al, it was seen that the sensitivity was 
82% and specificity was 70% for  diabetic peripheral neuropathy (DPN) and was 
much lower for detection of small fibre neuropathy. Here the gold standard used 
for DPN was an abnormal NCS and Diabetic neuropathy Symptom Score of more 
than two. The gold standard for small fibre neuropathy was normal NCS, and 
abnormal thermal testing and Diabetic neuropathy Symptom score of more than 2. 
(29) 
Armstrong et al used the presence of ulcer as a gold standard. This is the most 
reliable gold standard tool among all the available ones as the diseased and not 
diseased are clearly evident. According to this study, the sensitivity of 
biothesiometry was 95% and specificity was 65%. By combining other screening 
tools, such as Semmes Weinstein monofilament, or a neuropathy questionnaire 
with biothesiometer, there was a definite increase in specificity with a little or no 
decrease in sensitivity. (31) 
Some studies have taken VPT (Vibration perception threshold) as the gold 
standard for diagnosis of peripheral neuropathy. However there is a difference in 
the cut off to define neuropathy. While certain studies have used 15 as the cut off 
(34,35) ,others have used 25 volt as cut off.(32) Some people have graded the 
severity based on the value of VPT. (36) 
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Young et al has shown that the cumulative incidence of foot ulcers in patients with 
a VPT of <15V is 2.9% and that of patients with a VPT of > 25V is 19.8% 
indicating a seven times increased risk of ulceration when the VPT is more than 
25V when compared to a VPT of less than 15V. (34) This means that the patients 
with a VPT of more than 25V have to be explained the higher risk of ulceration 
and taught adequate foot care practices. The patients with biothesiometry values 
between 15V and 25V need to be advised strict glycemic control to at least delay 
the progression of peripheral neuropathy. This group of patients should be under 
regular follow up as well. 
Studies have shown that age plays a significant role in reduction of vibration 
perception. However there is not much effect of gender. There is no right left 
variation for vibration perception. (36) 
Dipa Saha et al conducted a study to assess if VPT testing can be applied in our 
country to diagnose diabetic peripheral neuropathy early(37). They had taken 60 
diabetic patients, 30 with clinical evidence of neuropathy and 30 without clinical 
evidence of neuropathy based on Michigan Neuropathy screening instrument. In 
the group with clinical neuropathy, 26.6% had no neuropathy based on VPT using 
biothesiometer. This could be attributed to the fact that biothesiometry is a 
subjective test. Majority of the patients with clinical evidence of neuropathy had 
grade 2 severity according to biothesiometry. 60% of the patients without clinical 
evidence of neuropathy had grade 1 severity of neuropathy according to 
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biothesiometry. This shows that VPT testing using biothesiometer can pick up sub 
clinical cases of peripheral neuropathy and this could help in early institution of 
therapy, better glycemic control and prevention of disease progression. 
Role of Nerve Conduction Studies: 
Nerve conduction studies are considered the most reliable, accurate, sensitive, 
specific and validated diagnostic test to assess peripheral nerve function.(39,40) 
They are objective and non invasive tests which have long been considered 
minimal criteria or the gold standard for diagnosis of neuropathy(41). NCS is done 
for both motor and sensory nerves.  
 
 
Figure 3: Measurement of Compound Motor Action Potential (CMAP) 
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For motor nerves, the stimulation is done in an orthodromic direction and a compound 
motor action potential is obtained.  (Figure 4).  For sensory nerves, the electrical 
stimulation is applied in the antidromic direction and a sensory nerve action potential is 
obtained(Figure 5).The nerves usually tested are radial, median and ulnar sensory and 
motor nerves of the upper limb and sural, superficial peroneal sensory and tibial and 
common peroneal motor nerves of the lower limbs.  The parameters looked into are distal 
latency, amplitude and conduction velocity. However, it is important to decide how many 
nerves, which nerves and which parameters to assess.  When we take all these parameters 
of so many different nerves, the next question that arises is how to interpret the data 
Figure 4: Measurement of Sensory Nerve Action Potential (SNAP) 
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and how to come to a conclusion whether the patient has diabetic neuropathy or not. 
The American Academy of Neurology(AAN) and PMR and Electrophysiology came to a 
consensus and their criteria said that when any two attributes of any two nerves, one 
being the sural nerve is affected, then a diagnosis of diabetic peripheral neuropathy can 
be made.(42) 
In diabetic neuropathy, sensory, motor and autonomic involvement is seen. Motor and 
sensory abnormalities can be picked up by NCS with sensory nerves being affected more 
than motor nerves, however autonomic neuropathy gets missed. Of the large and small 
nerve fibres, myelinated and unmyelinated fibres, nerve conduction studies mainly assess 
the large myelinated fibres.  
It is well known that the most common form of diabetic peripheral neuropathy is distal 
symmetric sensorimotor polyneuropathy which is length dependent and is predominantly 
sensory.  As the severity of the disease increases, there is progressive involvement of 
motor fibres as well. An experimental animal modal study done on Streptazocin induced 
experimental diabetes, in mice with a duration of diabetes being 8 months, showed that in 
motor neurons, there were progressive features of distal loss of axonal terminals but there 
was no perikaryal dropout, indicating distal axon retraction. As the cell bodies in the 
axons are preserved, there is more of conduction velocity slowing and eventually loss of 
motor neurons with single motor unit action potential enlargement. There is a subsequent 
decrease in amplitude. This suggests that when compared to sensory neurons, motor 
neurons are resistant to the effects of diabetes, however they are eventually targeted by 
diabetes and undergo degeneration.(43) 
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As the progression of diabetic neuropathy is centripetal, the involvement of the most 
distal muscles occurs first and then the disease process advances proximally. A study was 
done on the axonal dysfunction in diabetic peripheral neuropathy, on 40 patients where 
the motor unit potentials were recorded from the Extensor Digitorum Brevis and were 
compared with the motor nerve conduction velocity and distal motor latency of the lateral 
popliteal nerve or the common peroneal nerve. Classical feature of diabetic neuropathy is 
axonal dysfunction with concomitant collateral reinnervation which parallels 
demyelinating lesions. The collateral reinnervation is one explanation to subclinical 
neuropathy being picked up by nerve conduction studies. In this study, they have 
observed that the fastest motor nerve conduction velocity is affected in diabetics with 
clinical neuropathy more than in those without. This has a positive correlation with the 
motor unit numbers as well. There is a negative correlation with age and duration of 
diabetes, which indicates that the higher the age and the higher the duration if diabetes, 
the conduction velocity and motor unit numbers are significantly affected.(44) 
Some limitations have been identified with EDB, that is, since it is an intrinsic foot 
muscle, it would be difficult to differentiate axonal loss due to trauma from axonal loss 
due to the biochemical changes in diabetes.  Keeping in view the centripetal progression, 
the next muscle to be affected would be Tibialis Anterior. Hence one study was done to 
investigate the motor unit loss in Tibialis Anterior. Another advantage quoted was that 
more loss of motor units is expected in a more functional muscle like Tibialis Anterior. 
They showed that there was 40% decrease in the CMAP amplitude, 50% increased single 
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motor unit action potential, signifying reinnervation and 60% decrease in motor units, 
indicating that the denervation is outpacing the collateral reinnervation.  
The normative data for Nerve conduction tests must be standardized for every particular 
population as they vary very much with the ethnicity. They also have to be adjusted for 
age, height and gender. There are studies showing that there is a significant negative 
correlation for amplitude and conduction velocity, with age and height. (45,46)  The fact 
that various factors affect the rate of nerve conduction make it a weak measure in the 
prediction of severity of peripheral neuropathy.  Nerve conduction studies require 
specialized equipment and need expertise to perform. They are time consuming and 
complex. Technical errors can occur in patients with obesity.     
Despite all the limitations in the applicability of NCS, it is a  reproducible, objective and 
convenient measure for early detection of diabetic neuropathy and prediction of relevant 
late stage complications. It has also been found to correlate with the morphological 
findings of nerve biopsy. (47) NCS definitely have an important role in early detection 
and prediction of diabetic neuropathy, before clinical presentation. Hence they are 
fundamentally the most widely accepted test for diagnosis of diabetic peripheral 
neuropathy.(39) 
In 1994, Feldman et al said that NCS alone was not enough for diagnosis of DPN, it had 
to be combined with clinical testing and this was called the MDNS (Michigan Diabetic 
Neuropathy Score)(48) . The 1998 San Antonio Consensus Statement said that multiple 
assessments including evaluation of symptoms, eliciting clinical signs, electrodiagnostic 
studies, Quantitative sensory testing and autonomic function testing are needed for proper 
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diagnosis and classification of Diabetic neuropathy.(49) However, the AAN criteria 
suggested that patients with abnormal NCS had a relatively high likelihood of the 
condition. It has recently been proposed that any NCS abnormality with signs and 
symptoms confirm the diagnosis of Diabetic peripheral neuropathy, abnormal NCS  
without clinical signs and symptoms are suggestive of subclinical neuropathy, signs and 
symptoms without an abnormal NCS are suggestive clinical or small fibre 
neuropathy.(50,51) Pourhamidi et al showed that  in the impaired glucose tolerance 
population, there is a higher prevalence of small fibre neuropathy(32%) than distal 
symmetric peripheral neuropathy(12%), whereas in the group with Type 2 DM, the 
prevalence of small fibre neuropathy(28%) was similar to that of  distal symmetric 
peripheral neuropathy(30%). (29) 
 
Role of Sural Radial Amplitude Ratio (SRAR): 
Sural Radial Amplitude ratio (SRAR) is calculated by dividing sural sensory amplitude 
and radial sensory amplitude. As axonal polyneuropathy is characterized by distal 
degeneration of neurons, and the disease process is a length dependent one, it is expected 
that the sural radial amplitude ratio would be one of the earliest parameters to be affected. 
Hence this is considered a useful test in detecting diabetic polyneuropathy.(52) However, 
there are inconsistent results in literature, giving rise to doubts about its reliability and 
usefulness.(53,54) 
Again, there is no standard cut off for defining neuropathy by SRAR. One study had 
shown that a cut off of 0.4 had a high sensitivity and specificity (55), another study had 
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shown that a cut off of 0.34 was highly sensitive and specific(56), while another study 
has shown that majority of the normal persons have an SRAR of more than 0.21.(57) 
 
Rutvoke et al conducted a study among patients with a diagnosis of polyneuropathy 
based on clinical and electrophysiological criteria. Patients were included if they had at 
least two of the four parameters abnormal; including reduced vibratory sense below the 
knees, reduced pin prick and light touch distally in the legs, markedly reduced ankle 
reflexes or a distal to proximal gradient of chronic reinnervation and/or ongoing 
denervation on EMG in the leg. Thirty patients  and 30 age matched controls were 
included in the study. Of the 30 cases, 10 of them had diabetes mellitus, whereas the 
others had other reasons for polyneuropathy including alcoholism, late stage HIV, Renal 
failure, vasculitis, Crohn's  disease, chemotherapy and unknown causes. A cut off of 0.4 
for SRAR was used  and any value less than 0.4 was considered as abnormal. The 
sensitivity and specificity of SRAR was found to be 90%, much better than an individual 
sural SNAP amplitude which had a sensitivity of 66% and specificity of 93%. SRAR was 
not influenced by age, although sural amplitude was influenced by age. This eliminates 
the need for age based normative values and is hence more useful and convenient. This 
could be because the amount of influence of age on sural nerve as well as radial nerve is 
the same, hence the overall influence on SRAR was not significant. This suggests that the 
reduction in sensory amplitude due to increasing age is in part due to nerve loss, at the 
dorsal root ganglion, rather than only a length dependent process(55). The finding that it 
is not influenced by age is supported by another study in normal subjects by Overbeek et 
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al. It was also  identified that there was no influence of gender, height or weight on 
SRAR. (57) 
A study was done by Jung Bin Shin et al to assess the usefulness of minimal F wave 
latency and sural radial amplitude ratio (SRAR) in early diagnosis of diabetic peripheral 
neuropathy. They had selected diabetic patients with symptoms or signs of peripheral 
neuropathy and performed conventional NCV as well as minimal F wave  latency and 
SRAR in all these patients. They found that minimal F wave latency was prolonged in 
67% of the patients with a normal motor conduction velocity. Hence they concluded that 
minimal F wave latency is a more sensitive parameter than both conduction velocity of 
motor fibres and the amplitude of the compound motor action potential and therefore 
electrophysiological studies of diabetic patients must include F wave as a routine. 
However they observed a strong correlation of the increase in minimal F wave latency 
with that of slow conduction velocity. They also said that SRAR could be considered an 
additional sensory nerve conduction study, especially when sural sensor nerve conduction 
is not clearly diagnostic.(52) 
A study was done by Barnet et al in 49 diabetic patients, all of whom were diagnosed to 
have polyneuropathy based on a Consensus criteria. Out of these patients, 45 of them had 
neuropathy based on TCNS (Toronto Clinical Neuropathy Score). SRAR was done  in all 
the patients and it was found that only 39% of them had an abnormal SRAR, however 
74% had a low sural amplitude. It was concluded that SRAR had no added advantage 
when compared to sural amplitude  in picking up cases with peripheral neuropathy. The 
39 
 
reason for this was that a cut-off of SRAR  less than 0.21 was taken for diagnosis of 
neuropathy. (54) 
Papanasi et al studied the usefulness of sural sensory/radial motor amplitude ratio for the 
diagnosis of peripheral neuropathy in type 2 diabetic patients. They attempted to identify 
a potential new electrophysiological index that might correlate well with the standard 
NCS. Sural sensory amplitude/Radial motor amplitude ratio was the most useful 
diagnostic index, with 85% sensitivity, 71% specificity, 91% positive prognostic value, 
59% negative prognostic value and the highest overall agreement. Low levels of this ratio 
were associated with a nearly eightfold increase in the risk for NCS neuropathy. However 
this simple parameter cannot replace the entire nerve conduction studies in the diagnosis 
of diabetic peripheral neuropathy. This ratio, with a high sensitivity and a moderately 
high specificity, appears promising and merits further evaluation.(58) 
Some limitations of SRAR have been noted. It is a ratio of two separate nerves and hence 
any mild isolated neuropathy in either of the nerves can cause a big difference in the 
ratio. Technical precision is crucial for accurate values.  
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Role of minimal F wave latency:                                  
    
F wave is a small late response, an antidromic motor response, occurring after the 
CMAP.   It traverses the peripheral nervous system twice, once from the site of 
stimulation to the anterior horn cell, and then from the anterior horn cell back to the 
muscle innervated by the nerve stimulated(Figure 3). It evaluates the motor neurons and 
tells us about the excitability of the motor neuron pool. It was originally described by 
Magladery and Mc Dougal in the year 1950.(59) It is called F wave because it was first 
described in the foot muscles. However it is a ubiquitous response and can be recorded 
from all skeletal muscles. The F waves are characterized by variability in amplitude, 
Figure 5: Physiology of F wave 
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latency and configuration because different spinal motor neurons are stimulated with 
each stimulus. Hence at least 10-20 F waves have to be recorded with a supra maximal 
stimulus each time. The commonly used parameters include minimal F wave latency, 
mean F wave latency, maximum F wave latency, F wave dispersion or chronodispersion, 
F wave amplitude and F wave persistence.  
 
F waves are clinically commonly used to evaluate proximal nerve lesions for example 
lumbosacral radiculopathy and Gullian Bare Syndrome. Since diabetic neuropathy is a 
condition where the distal segment is more severely and early involved, F wave was not 
routinely used for the diagnosis. However due to its long pathway, for a diffuse 
peripheral lesion, even in early stages it will be reflected. Studies have said that minimal 
F wave latency is a useful parameter in early diagnosis of diabetic peripheral neuropathy. 
(60–62) However, some other studies have contradicted this fact. (63) 
A.R.Garate and A.G.Joshi conducted a study on utility of minimal F wave latency for 
diagnosis of peripheral neuropathy. They included 60 patients who were diagnosed with 
type 2 diabetes mellitus and had symptoms of peripheral neuropathy. Motor and sensory 
nerve conduction studies and F waves were performed in bilateral upper and lower limbs. 
It was found that the most sensitive parameter was minimal F wave latency. The changes 
in minimal F wave latency and distal motor latency (p<0.005) were more significant than 
the changes in the amplitude (p<0.01).  This could be attributed to the fact that initially 
there is loss of myelin sheath which leads to an increase in latency. Only when the axonal 
loss happens, the muscle fibre mass decreases and hence there is a decrease in the CMAP 
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amplitude. They also found that in 20.41% of the motor nerves studied, F wave minimal 
latency was increased while other motor conduction parameters like distal motor latency, 
motor nerve conduction velocity  and compound muscle action potential were normal. 
Another finding was that F wave latency was more affected in the upper limbs than in the 
lower limbs.(60) 
Barathi Taksande et al studied the usefulness of F wave latency measurement in the 
diagnosis of diabetic polyneuropathy. They said that the minimum F wave latency had a 
larger Z score or standard score than the motor conduction velocity and CMAP 
(compound motor action potential) amplitude of the median, ulnar, peroneal or tibial 
nerves, thus implying that F wave latency was affected more than the standard NCS 
parameters. There was a significant correlation between the minimum F wave latency and 
the motor conduction velocity in all the four motor nerves. This is because the slowing of 
nerve conduction is maximized by F waves travelling for long distances over the entire 
length of the nerve. (64) These findings coincide with that of Shin et al. (52) 
The big drawback is that when studies have compared F wave with conventional NCS 
parameters, they have not used any gold standard.  Most of the studies have included 
patients with symptoms of polyneuropathy, however have not quantified the 
symptoms.(60,64) The sensitivity and specificity are calculated based on the presence or 
absence of symptoms. If the clinical outcome measure was the presence or absence of an 
ulcer, then it would be reliable. However, when it comes to symptoms, it may be very 
subjective and without a proper screening system it would be difficult to rely on.  To 
identify whether it is more useful than conventional NCS there should be a tool better 
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than NCS that can be considered for comparison. However as such a tool doesn't exist, so 
the question arises, are we really picking up sub clinical cases or are we picking up false 
positive cases.  
Taha S Ahmed et al conducted a study to assess the usefulness of F-wave and sural 
potential in the diagnosis of subclinical diabetic neuropathy in patients from Saudi 
Arabia. This study was  different from previous studies in that diabetics without clinical 
signs and symptoms of neuropathy and normal subjects were the participants. They had 
shown that sural nerve sensory conduction velocity, sural SNAP amplitude, tibial and 
peroneal minimal F wave latency and F wave duration were significantly different 
between the two groups. Hence they concluded that minimal F wave latency and F wave 
duration of tibial and peroneal nerves were the first to be affected in sub-clinical 
peripheral neuropathy. (61) 
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JUSTIFICATION OF THE STUDY 
From literature what we infer is that there is a wide difference in the prevalence of 
diabetic peripheral neuropathy in various studies. This could be attributed to many factors 
including the lack of proper diagnostic criteria, gold standard test used, awareness of the 
population and other confounding factors like duration of diabetes. But the most 
important reason of all this would be the lack of diagnostic criteria. For example some 
studies have used VPT using biothesiometry as the gold standard whereas some studies 
have used nerve conduction studies as the gold standard. If we take nerve conduction 
studies, there is no single universal criteria followed. Similarly if we take VPT testing 
using biothesiometer, some studies use 15microV as the cut-off, while others  use only 
the value of more than 25microV to diagnose peripheral neuropathy. In this way sub-
clinical cases with neuropathy could be missed. 
Despite all the controversy, many studies have considered NCS as the gold standard as it 
is an objective and reliable test. However they are time consuming and difficult to do. In 
the present study comparison will be made between various outpatient screening tools 
(Michingan Neuropathy Screening Instrument,  biothesiometry, Semmes Weinstein 
Monofilament) and Nerve Conduction Studies. The diagnostic accuracy of each test when 
compared to NCS will be assessed. Biothesiometry is routinely being used in all patients 
presenting to the diabetic clinic. We would identify a few more simple tests to increase 
the sensitivity and specificity of diabetic neuropathy screening.  We would also be 
assessing the usefulness of minimal F wave latency and sural radial amplitude ratio in 
early diagnosis of diabetic peripheral neuropathy.  
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SUBJECTS AND METHODS 
 
This is a prospective cross-sectional study to compare the standard outpatient tools and 
nerve conduction studies in Diabetic peripheral neuropathy. The study was conducted in 
the Department of Physical Medicine and Rehabilitation. Forty eight patients with Type 2 
Diabetes Mellitus, aged between 30-65 years, who met the inclusion and exclusion 
criteria were enrolled from June 2015 to June 2016 after getting informed consent. 
Patients were recruited from the Endocrinology OPD, Diabetic foot clinic and Physical 
Medicine and Rehabilitation  OPD.  
 
Baseline demographic parameters such as age, sex and  duration of diabetes were 
assessed. A clinical proforma, which included a detailed history and examination was 
administered. Blood investigations, including fasting and post prandial sugars, HbA1C, 
Serum Creatinine and lipid profile were done. Michigan Neuropathy Screening 
instrument was administered and the patients were divided into two groups –Group 1 
without clinical neuropathy and Group 2 with clinical neuropathy. There were 28 patients 
without clinical neuropathy and 20 patients with clinical neuropathy. Thereafter, 
monofilament testing, biothesiometer and nerve conduction studies were done in both 
groups.  
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Diagrammatic Algorithm  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment for eligibility and recruitment (Patients diagnosed with Type 2 Diabetes Mellitus, n=48) 
 
Informed consent taken (n=48) 
 
Proforma  administered (including history, examination, BMI and blood 
investigations) 
 
MNSI administered by the principle investigator .Based on the MNSI examination 
score, patients were divided into two groups 
 
Group 1- Patients without 
clinical evidence of 
neuropathy 
MNSI Examination score < 2 
(n = 28) 
 
Group 1- Patients with clinical 
evidence of neuropathy 
MNSI Examination score > 2 
(n = 20) 
 
Semmes Weinstein 2, 4 and 10 gram monofilament test was used IN BOTH GROUPS 
by the diabetic foot clinic nurse at 10 sites 
Biothesiometry was performed IN BOTH GROUPS by the diabetic foot clinic  nurse  
 
Nerve conduction studies (NCS), including F wave was performed IN BOTH THE 
GROUPS by the principle investigator 
A ratio of the sural sensory and radial sensory amplitude of the SNAP was taken and 
used as SRAR (Sural radial amplitude ratio) 
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Participants: 
Inclusion Criteria: 
Patients between 30to 65 years of age diagnosed to have Type 2 diabetes mellitus 
Exclusion Criteria: 
1. Patients with ulcers/ amputations 
2. Patients with other diseases which affect the peripheral nerve function like 
malnutrition, alcoholism, familial and chronic liver disease, chronic kidney 
disease. 
3. Clinical evidence of any other peripheral nerve lesions/ lumbosacral 
radiculopathy/ lumbar canal stenosis  
4. Patients with cardiac pacemaker/cardiac rhythm abnormalities. 
5. Patients with Charcot foot 
6. Patients with obesity (Absence of SNAPs in these patients could be due to 
technical errors) 
 
The following tests were done. 
1. MICHIGAN NEUROPATHY SCREENING INSTRUMENT: 
PART 1 of this instrument is a self-administered Questionnaire.(Annexure 6) 
Responses of “yes” to items 1-3, 5-6, 8-9, 11-12, 14-15 are each counted as  one 
point.  A “no” response on items 7 and 13 counts as 1 point.  Item 4 is a measure 
of impaired circulation and is not included in the score.  Item 10 is a measure of 
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general asthenia and is not included in the score. A higher score (out of a 
maximum of 13 points) indicates more neuropathic symptoms.  
PART 2 Brief Physical Examination 
This has the following components: 
A. Foot Inspection:  
Bothfeet were inspected for evidence ofdry skin, callous formation, fissures, 
infection  and deformities such as  flat feet, hammer toes, overlapping toes, hallux 
valgus, joint subluxation, prominent metatarsal heads, medial convexity (Charcot 
foot) and amputation.  
Each foot with any abnormality receives a score of 1 for each side. 
B. Presence or absence of ulcer: 
Each foot with an ulcer receives a score of 1 for each side. 
C. Assessment of vibration sense on the dorsum of the great toe:  
This test was performed with the great toe unsupported. The test was done 
bilaterally - 128 Hz tuning fork was placed over the dorsum of the great toe on the 
bony prominence of the DIP joint. Normally, the examiner should be able to feel 
vibration in his or her hand for 5 seconds longer than a normal subject can at the 
great toe. 
 Scoring: 
Present – if examiner sensed the vibration on his or her finger for < 10 seconds 
longer than the subject felt it in the great toe– scored as 0 
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Reduced – if examiner sensed the vibration on his or her finger  for ≥ 10 seconds  
than the subject felt it in the great toe–scored as 0.5 for each side.  
Absent – if no vibration was detected by the patient–scored as 1 for each side 
  
 D. Grading of ankle reflex: 
Ankle reflex is elicited and if the reflex is absent the patient is asked to do the 
Jendrassic manoeuvre and if present , the reflex is designated as present with 
reinforcement. 
Scoring: 
Present - 0 
Present with reinforcement - 0.5 
Absent - 1 
 
E. Monofilament testing using Semmes Weinstein 10 g monofilament: 
The foot was kept supported. The filament was initially pre-stressed(4-6 
perpendicular applications to the dorsum of the examiner’s first finger).The 
monofilament was applied to the  dorsum of the great toe midway between the nail 
fold and the DIP joint. The filament was applied perpendicularly and briefly, (<1 
second) with an even pressure. When the filament bends, the force of 10 grams has 
been applied. The patient whose eyes were closed was asked to respond yes if he 
felt the filament. 
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Scoring: 
Normal: Eight correct responses out of 10  –scored as 0 
Reduced: One to seven correct responses–scored as 0.5 
Absent: No correct answers –scored as 1 
 
The total possible score of the part B of the  Michigan Neuropathy Screening 
Instrument is 10. Patients were divided into two groups based on this test. A score 
of more than 2 was considered to be positive for neuropathy. 
 
2. VIBRATION PERCEPTION TESTING USING A BIOTHESIOMETER: 
The Biothesiometer was applied perpendicular to the test site with a constant and 
firm pressure. It was performed using a Vibrometer-VPT machine, number 
V114012706  (Diabetic Foot Care India Private Limited) 
 
 Figure 6a: A biothesiometer 
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The vibration proprioception  was measured over the first DIP joint of both the 
legs. The voltage was slowly increased at the rate of 1 mV/sec and the vibration 
perception testing  value was defined as the voltage level when the subject 
indicated that he or she first felt the vibration sense.  
The mean of three records was taken. 
Scoring: 
<15mV – normal 
15-25mV – mild neuropathy 
25-40mV – moderate neuropathy 
>40mV - Severe neuropathy 
 
 
 
 
Figure 6b: Vibration 
perception testing with the 
vibration probe over the first 
DIP joint 
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3. SEMMES WEINSTEIN 2, 4 AND 10 GRAM MONOFILAMENT TESTING: 
        The foot was supported. Initially –pre-stress was done (4-6 perpendicular 
applications to the dorsum of the examiner’s first finger). 2, 4 and 10 gram 
monofilaments were used. 
 
 
 
 
The filaments were applied to 10 sites including 9 plantar sites and 1 dorsal site. The 
plantar sites included the  ventral aspect of digits 1,3 and 5; metatarsal heads (1,3,5), 
medial and lateral midfoot and heel. The dorsal site was the site between the base of 
digits 1 and 2. The filament was applied perpendicularly and briefly, (<1 second) with 
an even pressure. When the filament bends, the force of 2/4/10 grams has been 
applied(Figure 6). More than or equal to5 incorrect responses out of 10 in one foot 
indicated the  presence of neuropathy. 
 
Figure 7: Semmes Weinstein Monofilament Testing 
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4. NERVE CONDUCTION STUDIES: 
   Nerve conduction studies were performed on a Medelec synergy system (Multi sync 
LCD1770NX) with a room temperature of 23degrees. These studies were done using  
standard surface stimulating and recording techniques. Electrodes were coated with 
electro conductive gel and held in place with adhesive tape. 
 
 
Figure 8:Performing the sural  
sensory nerve conduction study 
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The following studies were done: 
i. Motor NCV was measured by electrical stimulation of a peripheral nerve and recorded 
from a muscle supplied by the nerve. The time taken for the electrical impulse to travel 
from the stimulation to the recording site was measured as the  latency  measured in 
milliseconds (ms). By stimulating in two different locations along the same nerve, the 
NCV(conduction velocity) across different segments could be determined. Calculations 
were performed by dividing the distance between the proximal and distal sites of 
stimulation by the differences in latencies (ms) to obtain nerve conduction velocity (m/s). 
The compound motor action potential amplitude (CMAP) amplitude was also measured. 
This was done for median, ulnar, tibial and common peroneal nerves 
ii. Sensory NCV was measured by electrical stimulation of a peripheral nerve and 
recording from a purely sensory portion of the nerve, such as on a finger. Like the motor 
studies, sensory latencies are on the scale of milliseconds. The sensory NCV was 
calculated based upon the latency and the distance between the stimulating and recording 
electrodes. SNAP Amplitude of Sural, Superficial peroneal, radial and median nerves was 
also measured. 
iii. Minimal F wave latencies of tibial, peroneal, median and ulnar nerves were recorded 
using a supramaximal stimulus with antidromic stimulation.  
iv. Sural radial Amplitude ratio (SRAR) was calculated by dividing the SNAP amplitudes 
of sural and radial nerves.  
**Nerve conduction studies were done in 25 normal subjects. Data was analysed. 
The mean and standard deviation was calculated for every parameter. Mean + 2SD 
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was taken as the cut off for latency and mean - 2SD was taken as the cut off for 
amplitude and conduction velocity.  Based on this it was determined whether each 
parameter was normal or abnormal.  
**For SRAR (Sural Radial Amplitude Ratio) >0.4 was considered as normal. (55) 
**For minimal F wave latency normal values were taken from an Indian study, 
done in Gujarat, in 59 subjects and published in 2013. (59) 
***According to the American Academy of Neurology, the American Association 
of Electrodiagnostic Medicine, and the American Academy of Physical Medicine 
and Rehabilitation, there were many previous recommendations regarding NCS 
criteria for the diagnosis of polyneuropathy, but no formal consensus existed.  
The following recommendation based on electrophysiologic principles combine 
both the highest sensitivity and specificity as well as the highest efficiency for the 
diagnosis of distal symmetric polyneuropathy. Hence the following recommended 
protocol for nerve conduction studies was used to determine the presence or 
absence of neuropathy.  
 
This protocol included unilateral studies of sural sensory, ulnar sensory, and 
median sensory nerves, and peroneal, tibial, median, and ulnar motor nerves with 
F waves. The minimum case definition criterion for electrodiagnostic 
confirmation of distal symmetric polyneuropathy is an abnormality ( 99th or 
1st percentile) of any attribute of nerve conduction in two separate nerves, 
one of which must be the sural nerve.(42) 
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Nerve conduction studies were done by the principal investigator under the 
supervision of PMR consultants who are co-investigators in the study. The entire 
procedure of NCS is mentioned in Annexure 7.  
 
OUTCOME MEASURES: 
1. CMAP amplitude, latency and conduction velocity of tibial, peroneal, median 
and ulnar nerves 
2. SNAP amplitude, latency and conduction velocity of radial, median, ulnar, sural 
and superficial peroneal nerves  
3.Minimal F wave latency of tibial, peroneal, median and ulnar nerves 
4. SRAR (sural radial amplitude ratio) 
5. Presence or  absence of neuropathy based on the minimum voltage at which the 
patient first felt vibration sense while testing with a biothesiometer 
6. Presence or absence of neuropathy based on the number of points perceived by 
a 2, 4 and 10 gram Semmes Weinstein Monofilament.   
7. Presence or absence of neuropathy based on Michigan Neuropathy Screening 
Instrument examination score. 
8. Michigan neuropathy screening instrument history score. 
9. Blood investigation to assess glycemic status and nephropathy - Haemoglobin, 
Glycosylated Haemoglobin, fasting plasma glucose , Post prandial blood glucose, 
Serum Creatinine, Fasting serum lipid profile, Urine microalbumin. 
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Predictors of diabetic peripheral neuropathy: 
1. Glycemic control( HbA1c, fasting blood glucose and post prandial blood 
glucose ) 
2. Duration of Diabetes 
Confounding factors:   
1. Age 
2. Gender  
3. Diabetes duration  
4. Current smoking  
5. Systolic blood pressure  
6. Waist circumference  
7. Height  
8. Peripheral arterial occlusive disease  
9. Glycosylated hemoglobin 
10. Estimated glomerular filtration rate  
11. Lipid profile. 
12. Microalbuminuria 
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Statistical Analysis: 
a. Sample size 
Two Means - Hypothesis testing for two means 
 
SURAL_SENSORY 
Standard deviation in group  I  3.93  
Standard deviation in group  II  6.76  
Mean difference  3.41  
Effect size  0.637979  
Alpha error (%)  5  
Power (1- beta) %  80  
1 or 2 sided  2  
Required sample size per group  41  
 
With reference to Diabetics and Metabolic syndrome: Clinical research and 
reviews 8(2014)48-52. Table 5 the NCV results for Sensory Sural nerve of the 
Left leg was found to be 55.55±3.93 and 52.14±6.76 for patient without clinical 
neuropathy and with clinical neuropathy respectively. With alpha error at 5%  and 
power at 80% for a two sided test we need to study 41 patients with clinical 
evidence of diabetic peripheral neuropathy and 41 patients without clinical 
evidence of diabetic peripheral neuropathy. 
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Data entry was done using MS excel. Data was summarized using mean(SD) for normal 
data, median(range) for skewed data, for continuous variables and frequency(percentage) 
for categorical data. 
Data was analysed using STATA/IC 13.1.  
The mean (SD) of latency, amplitude and conduction velocity of normal nerves were 
calculated and mean +/- 2SD was used to divide the values into normal and abnormal. 
The normal and abnormal NCS (nerve conduction studies) groups were taken as outcome 
and further analysis was done.  
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The baseline characteristics among the clinical neuropathy and the clinically silent group 
were compared using Independent T test/ Ranksum test for continuous variables and chi 
square test for categorical variables.  
The associations between MNSI and other categorical variables as well as NCS and other 
categorical variables were analysed using Chi Square test.   
The diagnostic accuracies( sensitivity, specificity, positive predictive value and negative 
predictive value) were calculated comparing the NCS normal and abnormal group, taking 
NCS as gold standard. Kappa statistics was used to check the agreement between NCS 
and biothesiometer, and NCS and MNSI (Michigan Neuropathy Screening Instrument).   
Correlation between amplitude and conduction velocity was analysed using Pearson 
correlation coefficient and scatter plots were presented.  
Comparison between Neuropathy based on NCS and Age, gender, duration of diabetes, 
BMI, HbA1C and MNSI History Score were done using Independent T test and Ranksum 
test to explore the relation.  
A multivariate logistic adjustability for age and HbA1C with NCS as the gold standard 
was analysed to study the risk of influence of age and HbA1C over the presence of 
neuropathy by NCS.  
The initial sample size calculated was 41 per group ( without and with clinical 
neuropathy). However after reaching a sample size of 28 in the group without clinical 
neuropathy and 20 in the group with clinical neuropathy the significance and power of 
the study were looked into. For sural conduction velocity, a significance with a p value of 
0.0139 was achieved, however the power was less than 80%. For Sural amplitude the p 
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value was 0.0003 and the power was 91%. There was a good correlation between sural 
amplitude and conduction velocity. This was a pilot study and it was stopped at this 
point. We plan to continue the study after submission of thesis to attain a better sample 
size.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
62 
 
RESULTS: 
 
During the study period of 1 year, 48 patients with type 2 Diabetes  who satisfied the 
exclusion and inclusion criteria were recruited. Michigan Neuropathy Screening 
Instrument (MNSI), biothesiometry, Semmes Weinstein Instrument screening and Nerve 
conduction studies including F wave studies and Sural Radial amplitude ratio were done 
for all the patients. 
 
1. BASELINE CHARACTERISTICS: 
 
Of the total 48 patients, 36 were males and 12 were females. The mean age was 51.31 
years and the mean duration of diabetes was 5.95 years. The mean BMI was 24.95kg/m
2 
and mean HbA1C was 8.21. All the patients recruited were on treatment for diabetes 
mellitus with either insulin or OHAs.Based on the scores of MNSI, the patients were 
divided into 2 groups- Group 1 with no evidence of clinical neuropathy and Group 2 with 
evidence of clinical neuropathy i.e. MNSI examination score of >/=2. 
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Table 1: Baseline Characteristics: 
 Group 1 
Mean(SD) 
Group 2 
Mean(SD) 
P value 
 
Age 48.18(6.76) 55.7(7.39) 0.00065 
BMI 24.32(3.01) 25.82(2.81) 0.08 
HbA1C 8.28(2.15) 8.1(1.73) 0.756 
Duration of Diabetes 
Median (Min,Max) 
4(0.2,15) 6(0.2,20) 0.39 
 
 
 
 
The above table shows that the mean age of patients without clinical neuropathy was 
48.18(6.76) and the mean age of patients with clinical neuropathy was 55.7(7.39) and the 
difference  was statistically significant (p=0.00065). The median duration of diabetes was 
4 years (0.2,15) in the group without clinical neuropathy  and 6 years (0.2,20) in the 
group with clinical neuropathy and this difference was not statistically significant. The 
mean HbA1C was 8.28(2.15) and 8.1(1.73) in the patients without clinical neuropathy 
and those with clinical evidence of neuropathy. This difference was not statistically 
different. The mean BMI (body mass index) in the patients with and without clinical 
neuropathy was 25.82(2.81) and 24.32(3.01) respectively. 
 
BMI - Body Mass Index, HbA1C - glycosylated haemoglobin, MNSI  - Michigan 
Neuropathy Screening Instrument, SD - Standard Deviation 
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2. DIAGNOSIS OF DIABETIC PERIPHERAL NEUROPATHY 
 
2.1 Diagnosis of diabetic neuropathy based on MNSI 
Based on Michigan Neuropathy Screening Instrument, 58.33% patients had diabetic 
peripheral neuropathy . 
 
Fig 2.1. Diagnosis of Diabetic Neuropathy based on Michigan Neuropathy Screening 
Instrument(Clinical Neuropathy) 
 
 
 
 
 
  
20(41.66%) 
28(58.33%) 
Clinical neuropathy
No clinical neuropathy
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2.2 Diagnosis of Diabetic Neuropathy based on Biothesiometry: 
According to biothesiometry, with a 15 mV cut off,  43.75% of patients had no 
neuropathy, 37.5% had mild neuropathy, 6.25% had moderate neuropathy and 12.5% had 
severe neuropathy.  Thus a total of 56.25% patients were found to have neuropathy based 
on biothesiometry. 
Table 2.2 Diagnosis of Diabetic Neuropathy based on Biothesiometry 
Biothesiometer Number(Percentage) 
Normal 21(43.75%) 
Minimal 18(37.5%) 
Moderate 3(6.25%) 
Severe 6(12.5%) 
 
 
2.3. Diagnosis of Diabetic Neuropathy based on nerve conduction studies: 
With the nerve conduction studies, only 14/48 (29.16%) were found to have neuropathy. 
Twenty seven percent of the patients had abnormalities in conduction velocity and 20% 
had abnormality in amplitude. An abnormal sural radial amplitude ratio (a computed ratio 
from nerve conduction studies) was noticed in 85.41% patients and abnormal F wave was 
seen in 45.83% of patient. 
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2.4 Diagnosis of Diabetic Neuropathy based on various screening tools: 
 
 
 
 
 
 
 
The above figure shows that 29.16% of the patients are diagnosed with neuropathy based 
on nerve conduction studies, 56.25% of the patients are diagnosed based on 
biothesiometer with 15V as cut off, 8.3% based on Semmes Weinstein Monofilament, 
41.66% based on MNSI, 85.41% based on SRAR and 45.83% based on F wave.  
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
BT(15V as
cut off)
NCS SRAR F wave SWMF MNSI
56.25% 
29.16% 
85.41% 
45.83% 
8.30% 
41.66% 
Fig 2.4Diagnosis of Diabetic Peripheral Neuropathy according to 
various screening tools 
BT - Biothesiometer; NCS - Nerve Conduction Studies; SRAR - Sural Radial 
Amplitude Ratio, SWMF - Semmes Weinstein Monofilament; MNSI - Michigan 
Neuropathy Screening Instrument 
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3. COMPARISON OF VARIOUS SCREENING TOOLS FOR DETECTION OF  
DIABETIC PERIPHERAL NEUROPATHY 
3.1 Relation between Clinical Neuropathy based on MNSI and Nerve conduction 
studies: 
 
 
Fig 3.1. Clinical Neuropathy based on Michigan Neuropathy Screening Instrument 
and Nerve conduction studies 
This bar graph shows that in the group with no clinical evidence of neuropathy, 82.14% 
also have normal nerve conduction studies(NCS), whereas 17.8% have been diagnosed to 
have clinically silent neuropathy by NCS. However in the group with clinical neuropathy,  
45% are diagnosed by NCS, the rest 55% have normal NCS. The correlation was 
significant with a p value of 0.041.Of the 14 patients with an abnormal NCS, 9 patients  
(64.28%) had clinical evidence of neuropathy. 
The agreement between MNSI and NCS was 66.67% with a kappa of 28.36 
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23 (82.14%) 
11 (55%) 
5 (17.86%) 
9 (45%) 
NCS Normal
NCS Abnormal
P value = 0.041 
*NCS - Nerve conduction studies 
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Table 3.1.1. Comparison of CMAP/SNAP conduction velocity between the two groups (with 
and without clinical neuropathy): 
 
The above table shows that there is a significant difference between the conduction 
velocities of right sural nerves (p value0.007), right superficial peroneal nerve (p value  
0.012) and bilateral tibial nerves (p values, 0.028 and 0.0075)  in the groups with and 
without clinical neuropathy.  
 
 
 
 
 
 
 Right Left 
 Group 1 Group 2 P 
value 
Group 1  Group 2 P 
value 
Sensory:       
Median 52.53(8.47) 48.96(12.65) 0.25 53.78(7.22) 48.46(5.87) 0.0092 
Radial 61.44(7.32) 62.63(10.77) 0.65 61.08(7.98) 60.02(11.26) 0.70 
Sural 47.15(15.06) 30.38(26.22) 0.007 46.49(10.95) 38.45(20.59) 0.09 
Superficial 
peroneal 
45.36(24.69) 25.52(27.81) 0.012 44.49(20.03) 36.54(26.86) 0.25 
       
Motor:       
Median 53.11(4.9) 47.67(10.91) 0.024 52.14(6.26) 51.45(5.13) 0.68 
Ulnar 57.45(6.87) 54.52(6.45) 0.14 56.17(7.74) 54.96(6.10) 0.56 
Common 
peroneal 
44.29(4.56) 40.98(7.31) 0.18 43.68(5.54) 41.07(7.77) 0.18 
Tibial 43.28(5.94) 39.51(5.34) 0.028 44.30(4.53) 40.16(5.75) 0.0075 
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Table 3.1.2. Comparison of CMAP/SNAP amplitude between the two groups (with and 
without clinical neuropathy): 
 
 Right Left 
Sensory: Group 1 Group 2 P 
value 
Group1 Group 2 P 
value 
Median 50.58(22.48) 36.37(22.17)  52.48(22.89) 41.19(17.75) 0.09 
Radial 64.56(24.60) 45.39(20.39)  65.41(27.66) 40.88(17.75) 0.06 
Sural  24.16(28.07) 8.65(8.56) 0.02 20.78(11.74) 11.11(7.84) 0.0025 
Superficial 
peroneal 
16.62(11.34) 8.92(11.14) 0.01 17.81(11.97) 10.32(10.05) 0.03 
Motor:       
Median 7.99(2.35) 7.71(2.95) 0.72 7.29(2.61) 7.06(2.68) 0.75 
Ulnar 8.75(3.04) 7.37(1.82) 0.07 8.39(2.59) 7.16(2.2) 0.09 
Common 
peroneal 
4.55(2.53) 3.69(2.69) 0.26 4.51(2.43) 4.57(4.81) 0.95 
Tibial 6.27(1.95) 5.52(4.33) 0.42 6.08(2.15) 4.79(2.92) 0.08 
       
 
The above table shows that there is a significant difference between the amplitudes of 
bilateral sural nerves (p values for right and left 0.02 and 0.0025 respectively) and 
bilateral superficial peroneal nerves  (p values, 0.01 and 0.03)  in the groups with and 
without clinical neuropathy.  
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3.2.Relation between Clinical Neuropathy based on MNSI(Michigan Neuropathy 
Screening Instrument) and Biothesiometer: 
 
 
Table 3.2 Relation between Clinical Neuropathy based on MNSI(Michigan 
Neuropathy Screening Instrument) and Biothesiometer: 
 
Biothesiometer Group 1 Group 2 
0 (<15 V) - Normal 18(64.29%) 3(15%) 
1 (15-25V) - Mild 8(28.57%) 10(50%) 
2 (25-40V) - Moderate 1(3.57%) 2(10%) 
3 (>40) - Severe 1(3.57%) 5(25%) 
P value = 0.001 
 
The above table shows that in the group with no clinical evidence of neuropathy, 64.29% 
have no evidence of neuropathy by biothesiometry, and 85% of the patients in the group 
with clinical neuropathy also have abnormal biothesiometry. The correlation was 
significant with a p value of 0.001. 
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3.3. Relation between Clinical Neuropathy based on MNSI(Michigan Neuropathy 
Screening Instrument) and Semmes Weinstein Monofilament testing: 
 
 
 
 
Fig 3.3 Bar graph showing Relation between MNSI and Semmes Weinstein Instrument 
 
The above graph shows that all patients without clinical neuropathy and 80% of the 
patients with clinical evidence of neuropathy were able to perceive a 2 gram Semmes 
WeinsteinMonofilament at more than 6 out of 10 points. Four patients had neuropathy 
based on Semmes Weinstein monofilament and all four of them belonged to the group 
with clinical neuropathy based on Michigan Neuropathy Screening Instrument. 
 
 
28 (100%) 
16(80%) 
0 (0%) 
4(20%) 
0% 20% 40% 60% 80% 100% 120%
Group 1
Group 2
SWMF Abnormal
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*SWMF - Semmes Weinstein 
Monofilament 
p value = 0.013 
 
72 
 
3.4.Relation between Sural Radial Amplitude Ratio(SRAR) and clinical neuropathy 
by Michigan Neuropathy Screening Instrument: 
 
 
 
 
Fig 3.4.Bar graph showing the Relation between Sural Radial Amplitude Ratio(SRAR) 
and clinical neuropathy by Michigan Neuropathy Screening Instrument 
 
This shows that only 2 patients with clinical neuropathy have a normal SRAR, the 
remaining  90% have an abnormal SRAR. Also, 82.1% of patients with no clinical 
evidence of neuropathy have an abnormal SRAR.  
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
Group 1 Group 2
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*SRAR - Sural Radial Amplitude ratio 
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3.5.Relation between symptoms based on Michigan Neuropathy Screening 
Instrument History Score(MNSI HS) and clinical neuropathy by Michigan 
Neuropathy Screening Instrument Examination Score(MNSI ES): 
 
 
Fig 3.5.Relation between symptoms based on Michigan Neuropathy Screening 
Instrument History Score(MNSI HS) and clinical neuropathy by Michigan Neuropathy 
Screening Instrument Examination Score(MNSI ES):  
 
The above bar graph shows that 75% of the patients in group 1 and 80% of the patients in 
group 2 have a normal history score of less than 4. This correlation is not statistically 
significant with a p value of 0.68.  
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 MNSI HS - Michigan Neuropathy Screening Instrument History Score 
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3.6.Relation between Nerve conduction studies and biothesiometer: 
 
Table 3.6.1. Relation between Nerve conduction studies and biothesiometer: 
 NCS normal NCS abnormal 
Biothesiometer Normal 18 (52.94%) 3 (21.43%) 
Mild neuropathy 14 (41.18%) 4 (28.57%) 
Moderate neuropathy 0 (0%) 3 (21.43%) 
Severe neuropathy 2 (5.88%) 4 (28.57%) 
 
When we compare nerve conduction studies and biothesiometer,32 out of 34 (94.11%) 
patients with normal NCS have either no neuropathy or mild neuropathy according to 
biothesiometry. Of the 14 patients with abnormal  NCS, 11(78.57%) could be picked up 
by biothesiometry.  
The agreement between biothesiometer and NCS is 79.17% with a kappa of 44.95.  
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Fig.3.6.1 Relation between Nerve conduction studies and biothesiometry 
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3.6.2 Comparison of conduction velocity between two groups based on biothesiometer 
 
 
The above table shows that there is a significant difference between the conduction 
velocities of bilateral sural nerves (right and left p values, 0.00 and 0.0007 
respectively),bilateral superficial peroneal nerves (p values, <0.001 and 0.023), bilateral 
common peroneal nerves (p values, <0.001 and 0.0013), bilateral tibial nerves (p values, 
0.004 and 0.01)  in the groups with and without neuropathy based on biothesiometer 
(25V as cut off).  
 
 
 
 Right Left 
 BT Normal BT 
abnormal 
P value BT Normal  BT 
abnormal 
P 
value 
Sensory:       
Median 52.53(7.93) 45.4(16.33) 0.05 52.61(6.35) 31.33(12.04) 0.046 
Radial 62.25(7.39) 60.72(13.43) 0.63 60.91(8) 59.59(13.98) 0.69 
Sural 47.21(15.73) 13.4(21.69) 0.000 46.99(10.05) 28.53(24.97) 0.0007 
Superficial 
peroneal 
44.37(24.62) 9.44(20.14) 0.00015 45.03(21.19) 26.54(25.72) 0.023 
       
Motor:       
Median  52.64(4.76) 44.01(14.25) 0.0025 52.54(6.09) 49.23(3.41) 0.11 
Ulnar 57.40(6.78) 51.77(4.86) 0.018 57.15(6.78) 50.05(5.23) 0.0036 
Common 
peroneal 
44.41(4.61) 36.8(7.41) 0.0003 44.07(5.78) 36.52(6.52) 0.0013 
Tibial 42.93(5.57) 37.06(5.18) 0.0043 43.57(4.37) 37.78(7.42) 0.011 
BT - Biothesiometer 
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3.6.3 Comparison of amplitude between two groups based on biothesiometer: 
 
 Right Left 
Sensory: BT Normal BT 
abnormal 
P 
value 
BT Normal  BT 
abnormal 
P 
value 
Median 50.43(21.89) 22.73(13.02) 0.0004 52.61(6.35) 47.59(8.82) 0.005 
Radial 62.60(22.92) 33.65(16.52) 0.0005 61.007(26.62) 33.09(11.88) 0.002 
Sural  21.17(24.74) 4.5(8.35) 0.042 19.13(10.86) 7.69(8.02) 0.0032 
Superficial 
peroneal 
15.96(10.96) 3.72(9.92) 0.002 16.5(11.77) 7.8(8.96) 0.035 
Motor:       
Median 8.16(2.74) 6.75(1.54) 0.13 7.41(2.71) 6.34(2.11) 0.24 
Ulnar 8.34(2.79) 7.52(2.09) 0.39 8.1(2.52) 7.01(2.28) 0.22 
Common 
peroneal 
4.57(2.61) 2.74(2.14) 0.05 5.01(3.69) 2.74(2.41) 0.07 
Tibial 6.60(3.03) 3.49(2.33) 0.004 6.07(2.43) 3.52(2.01) 0.003 
 
 
The above table shows that there is a significant difference between the amplitudes of 
bilateral sural nerves (0.04 and 0.003),bilateral superficial peroneal nerves (0.002 and 
0.035), bilateral tibial nerves (0.004 and 0.003), bilateral median nerves (<0.001 and 
0.005), bilateral radial nerves (<0.001 and 0.002)  in the groups with and without 
neuropathy based on biothesiometer (25V as cut off).  
 
 
 
 
BT - Biothesiometer 
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3.6.4.Relation between Nerve conduction studies and biothesiometer in the group 
without clinical neuropathy: 
 
 
Fig 3.6.4.Bar graph showing the relation between Nerve conduction studies and 
biothesiometer in the group without clinical evidence of neuropathy 
The above table shows that in the group of 28  patients without clinical evidence of 
neuropathy 17 out of 28 patients(60.71%) have both normal NCS and biothesiometer  
recordings, while 4 out of 28 patients(14.28%) have abnormal NCS and biothesiometer 
recordings, that is they have clinically silent neuropathy according to biothesiometry well 
as NCS. The correlation was statistically significant(p= 0.023) However 6 patients 
(21.43%) have a normal NCS despite an abnormal biothesiometer value and one patient 
has an abnormal NCS despite normal biothesiometer value.  Of the 6 patients with a 
normal NCS and abnormal biothesiometer value, 5 of them have mild neuropathy 
according to biothesiometer suggesting that mild neuropathy is better picked up by 
biothesiometer.  
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3.6.5.Relation between Nerve conduction studies and biothesiometer in the group 
with clinical evidence of neuropathy: 
 
 
 
Fig. 3.6.5.Bar graph showing relation between Nerve conduction studies and 
biothesiometer in the group with clinical evidence of neuropathy 
 
This table shows that among the 20 patients with clinical evidence of neuropathy, 7 
patients (35%) have both abnormal NCS and biothesiometer, while 10 patients, 
(50%)have an abnormal biothesiometer value despite a normal NCS. This shows that 
biothesiometer has picked up more cases of neuropathy in the clinically evident as well as 
clinically silent group.  
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79 
 
4. USEFULNESS OF SRAR AND MINIMAL F WAVE LATENCY: 
4.1.Comparison of Conventional Nerve conduction studies (NCS) and Sural Radial 
Amplitude Ratio(SRAR): 
 
  
 
Fig 4.1. Comparison between Conventional nerve  conduction studies and SRAR 
 
This bar graph shows that every patient with an abnormal NCS also had an abnormal 
Sural Radial Amplitude ratio (100%). Among patients with a normal NCS also, 80% 
have an abnormal SRAR. Considering nerve conduction studies as the gold standard, the 
sensitivity of Sural Radial Amplitude ratio is 100% and the Specificity is 20.6%. It has a 
positive predictive value of 34.1% and a negative predictive value of 100%, which means 
that a person with a normal Sural Radial Amplitude ratio definitely doesn't have the 
disease, however if a person has an abnormal Sural Radial amplitude ratio, there is only 
34.1% that he is truly diseased.  
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4.2. Comparison between NCS and F wave 
 
 
Fig.4.2.Comparison between NCS and F wave 
 
The above graph shows that 67.65% of the patients with normal conventional nerve 
conduction studies also have normal F waves and 78.57% of the patients with abnormal 
NCS also have abnormal F waves. This is statistically significant with a P value of 0.003.  
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Table 4.3. Comparison of minimal F wave latency between two groups ( with and 
without clinical neuropathy): 
 Right Left 
 Group 1 Group2 P 
value 
Group 1 Group 2 P 
value  
Median 26.84(1.86) 28.17(4.35) 0.16 27.11(2.24) 27.06(2.43) 0.95 
Ulnar 27.19(2.14) 27.77(2.26) 0.37 27.48(2.22) 28.12(3.02) 0.40 
Common Peroneal 46.69(6.86) 50.65(11.01) 0.13 48.34(6.88) 51.87(13.06) 0.18 
Tibial 46.69(7.32) 51.16(8.85) 0.06 47.09(7.09) 52.90(11.83) 0.04 
 
The above table shows that the minimal F wave latency is slightly prolonged in the group 
with clinical neuropathy than the group without clinical neuropathy, but significance was 
observed only for left tibial nerve (0.04).  
 
Table 4.4. Comparison of minimal F wave latency between two groups based on 
biothesiometry: 
 Right Left 
 BT Normal BT 
abnormal 
P value BT Normal  BT 
abnormal 
P value 
Median 26.64(1.49) 30.27(5.65) 0.0008 26.81(2.08) 28.15(2.83) 0.099 
Ulnar 27.02(2.02) 28.99(2.18) 0.009 27.08(2.11) 30.28(2.71) 0.00021 
Common 
Peroneal 
45.96(7.46) 57.37(8.63) 0.0001 46.81(7.24) 61.21(10.96) 0.000 
Tibial 46.67(6.80) 55.67(9.52) 0.001 46.65(7.01) 60.40(11.03) 0.000014 
 
BT - Biothesiometer 
82 
 
The above table shows that the difference of mean minimal F wave latency between the 
two groups with and without neuropathy based on biothesiometry was significant for all 
nerves.   
 
 
 
 
 
 
 
 
 
NCS - Nerve Conduction Studies; BT - Biothesiometer; SRAR - Sural Radial 
Amplitude Ratio 
Flow chart showing the distribution of abnormalities in various screening tests 
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Of the total 48 patients, 28 of them didn't have clinical evidence of neuropathy and 20 of 
them had clinical evidence of neuropathy.  
In the group with clinical evidence of neuropathy, 9 patients (45%) had an abnormal 
NCS, out of which all the 9 had an abnormal SRAR, 8 of them had an abnormal F wave 
and 7 of them had a biothesiometer value of more than 15V.  Out of the 11 patients 
(55%) with a normal NCS, 10 of them had abnormal biothesiometry (cut off of 15V) and 
9 of them had abnormal SRAR.  
The group without clinical evidence of neuropathy is more important as it is the target 
group, where clinically silent neuropathy needs to be picked up. Of the 28 patients 
without clinical evidence of neuropathy, 5 of them have an abnormal NCS, 10 have 
abnormal biothesiometer recordings, 23 have abnormal SRAR values and 10 have 
abnormal F wave latencies. Of the  patients with abnormal NCS, all 5 have an abnormal 
SRAR and 4 of them have a biothesiometer value more than 15V.  
However, of these 28 patients, 23 of them have a normal NCS. Eighteen of them are 
picked up as abnormal by SRAR, 7 have an abnormal F wave and 6 of them have a 
biothesiometer value more than 15V.  
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5. SENSITIVITY AND SPECIFICITY OF THE VARIOUS SCREENIG TOOLS: 
 
Table 5.1.Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative 
Predictive Value (NPV) based on Nerve Conduction Studies (NCS) as the gold 
standard: 
 MNSI SWMF BT(15V 
as cut off) 
BT(25 V 
as cut off) 
SRAR F wave 
Sensitivity 64.3% 14.3% 78.6% 50% 100% 78.6% 
Specificity 67.6% 95.1% 52.9% 91.2% 20.6% 67.6% 
Positive 
Predictive Value 
45% 50% 40.7% 70% 34.1% 28.2% 
Negative 
Predictive Value 
82.1% 72.7% 85.7% 81.6% 100% 69.8% 
 
 
 
The above table shows that the most sensitive test is Sural Radial amplitude ratio, with 
100% sensitivity and 100% negative predictive value. Biothesiometer with 15V as cut off 
has a sensitivity of 78.6% and negative predictive value of 85.7%. The highest 
specificity, 95.1% is for Semmes Weinstein monofilament, however the sensitivity is 
only 14.3%. Biothesiometer with a cut off of 25V has a specificity of 91.2% and a 
negative predictive value of 70%.   
 
MNSI - Michigan Neuropathy Screening Instrument; SWMF - Semmes Weinstein 
Monofilament;  BT – Biothesiometer; SRAR - Sural Radial Amplitude Ratio 
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Table 5.2.Sensitivity and Specificity of combined parameters based on NCS as gold 
standard: 
 SRAR + BT (15V 
as cut off) 
SRAR + BT(15V as 
cut off) + MNSI 
SRAR + BT(25V as 
cut off) 
Sensitivity 78.6% 50% 50% 
Specificity 61.8% 76.5% 97.1% 
 
 
 
 SRAR + F wave SRAR + F wave + 
BT(15V) 
SRAR + F wave + 
BT(15V as cut off) 
+ MNSI 
Sensitivity 78.6% 71.4% 57.1% 
Specificity 82.4% 91.2% 91.2% 
 
 
 
By combining Sural Radial Amplitude ratio with biothesiometer(15V as cut off), there is 
a considerable increase in specificity to 61.8%, with only a slight decrease in sensitivity, 
to 78.6%. The highest specificity 97% is got by combining Biothesiometry of 25V with 
SRAR. The highest sensitivity for the combined tools is for SRAR with Biothesiometer 
with 15V as cut off (78.6%) and SRAR with F wave(78.6%).      
 
BT - Biothesiometer; SRAR - Sural Radial Amplitude Ratio; MNSI - Michigan 
Neuropathy Screening Instrument 
BT - Biothesiometer; SRAR - Sural Radial Amplitude Ratio;MNSI - Michigan 
Neuropathy Screening Instrument 
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6. NERVE CONDUCTION ABNORMALITIES IN INDIVIDUAL NEREVES: 
Table 6. Nerve conduction abnormalities in upper and lower limb nerves: 
PARAMETER AFFECTED NUMBER OF PATIENTS(%) 
UPPER LIMB NERVES  
Median sensory amplitude 2 (4.2%) 
Median Sensory conduction velocity 12 (25%) 
Radial sensory amplitude 0 (0%) 
Radial sensory conduction velocity 0 (0%) 
Median Motor amplitude 1 (2.1%) 
Median motor conduction velocity 7 (14.58%) 
Ulnar amplitude 3 (6.25%) 
Ulnar conduction velocity 6 (12.5%) 
LOWER LIMB NERVES  
Sural Sensory amplitude 13 (27%) 
Sural sensory conduction velocity  10 (20.8%) 
Superficial peroneal sensory amplitude 14 (29.1%) 
Superficial peroneal sensory conduction velocity 16 (33.33%) 
Tibial amplitude 8 (16.6%) 
Tibial conduction velocity 6 (12.5%) 
Common Peroneal amplitude 16 (33.33%) 
Common peroneal conduction velocity 18 (37.5%) 
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The above table shows that lower limb nerves are more affected than the upper limb 
nerves, with the common peroneal nerve being the most commonly affected, followed by 
superficial peroneal nerve and sural nerve.  
7. CORRELATION BETWEEN AMPLITUDES AND CONDUCTION 
VELOCITIES: 
 
 
 
 
The above graph showed that there was a significant correlation between conduction 
velocities and amplitudes of all lower limb nerves with the highest for Superficial 
Fig 7.1:Correlation between amplitudes and conduction velocities for lower 
limb nerves 
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peroneal nerve (correlation coefficient of 0.69 and p<0.001), followed by sural nerve 
(correlation coefficient of 0.49 and p<0.001).     
 
 
 
The above graph showed that there was a significant correlation between conduction 
velocities and amplitudes of all upper limb nerves with the highest for median sensory 
nerve (correlation coefficient of 0.37 and p value of 0.009).   
 
  
Fig 7.2:Correlation between amplitudes and conduction velocities for upper 
limb nerves 
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8. ASSOCIATIONS WITH PERIPHERAL NEUROPATHY: 
 
Table 8.1.Association of  significant variables: 
Variables NCS Normal 
Mean(SD) 
NCS Abnormal 
Mean(SD) 
P 
value 
Age 49.41(7.32) 55.93(7.56) 0.0079 
BMI 24.75(2.89) 25.43(3.27) 0.48 
Duration of Diabetes 5.27(4.09) 7.61(6.09) 0.31 
HbA1C 7.72(1.83) 9.38(1.85) 0.0068 
MNSI HS 2.12(1.55) 2.21(1.63) 0.799 
 
 
 
The above table shows that age and HbA1C have a significant association with  (P values 
of 0.0079 and 0.0068 respectively) the presence of neuropathy diagnosed on the basis of 
nerve conduction studies.  
However, duration of diabetes and BMI do not significantly affect the presence of 
neuropathy based on nerve conduction studies.  
Gender also did not show a significant association with the presence or absence of 
neuropathy. (P value = 0.48).   
 
 
BMI - Body mass Index, MNSI HS- Michigan Neuropathy Screening Instrument 
History score 
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8.2.Multivariate Logistic Regression for significant variables: 
Multivariate logistic regression was done for the two variables which had a significant 
correlation on univariate logistic regression; namely age and HbA1C. 
 
Table 8.2.Multivariate Logistic Regression for significant variables: 
Variable Odds Ratio(95%CI) P value 
Age 1.16(1.04 o 1.29) 0.007 
HbA1C 1.85(1.18 to 2.9) 0.008 
 
 
The above table shows that for every 1 year increase in age, there is a 1.16 times more 
chance of developing neuropathy and with every one unit increase in HbA1C there will 
be 1.85 times more chance of developing neuropathy.  
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DISCUSSION: 
This is an observational, cross sectional study comparing various screening tools for early 
detection of diabetic peripheral neuropathy. It is known that there is a wide variability in 
the prevalence of diabetic peripheral neuropathy due to the fact that different studies have 
used different screening tools. In the current study it has been observed that the 
prevalence of diabetic neuropathy has varied widely depending upon the method of 
diagnosis and the screening tool used.  
Diabetic neuropathy was diagnosed in 29.16% patients with diabetes based on nerve 
conduction studies, which is the gold standard test. This was the same as two other Indian 
studies.  Gill et al found a similar prevalence of 29.2% in Lucknow, however their 
definition of neuropathy was based on Neuropathy symptom score(NSS) and Neuropathy 
Disability Score(NDS). (28) Dutta et al in his study among patients with recently 
diagnosed diabetes mellitus from Manipur also showed a similar prevalence of 29%. 
Neuropathy was diagnosed based on NSS, NDS and abnormal common peroneal nerve 
conduction studies.(6) Bagchi et al in his study among 50 normal people and 50 patients 
with diabetes reported a prevalence of neuropathy of 44%  in diabetics based on nerve 
conduction studies. The NCS was interpreted according to the American Academy of 
Neurology protocol, which is the same criteria used in our study.(65) 
A recent study showed that the prevalence of diabetic neuropathy was 97% according to 
nerve conduction studies. The reason for this wide difference could be the fact that they 
had taken nerve conduction studies as abnormal if any one parameter of any nerve tested 
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were abnormal, however as per our criteria at least two parameters had to be affected and 
one of those should include the sural nerve. (66) 
Of the total sample size of 48 patients, 58.33% had clinical neuropathy based on 
Michigan Neuropathy Screening Instrument with 2 as cut off in the examination score. 
Turkan mete et al reported that 32.07% of the patients had clinical neuropathy based on 
MNSI.(67) This was slightly lower than our study probably because the cut off score they 
used was 2.5 and our cut off was 2, hence the sensitivity was slightly lower.  
A study aimed at validation of Michigan Neuropathy Screening Instrument showed that 
as the cut off for defining clinical neuropathy increased, there is a decrease in sensitivity 
and an increase in specificity(cut off of 2 and 2.5 have a sensitivity of 65% & 50% and a 
specificity of 83% & 91% respectively.(20) Al Geffari et al showed that 45% of the 
patients had neuropathy according to MNSI. (30) 
In the current study, 56.25% of the patients had an abnormal biothesiometer value of 
more than 15 Voltsand 18.75% of the patients had a biothesiometer value of more than 25 
volts. This is similar to  Young et al’s study on 469 patients in which 55.44% of the 
patients had a biothesiometer value of more than 15 V.(34) A study done in Post 
Graduate Institute of Medical Education and Research, in Chandigarh on validation of 
bedside methods in evaluation of diabetic peripheral neuropathy, had taken 
biothesiometer as gold standard and compared other tools like Diabetic neuropathy 
symptom score and examination score with biothesiometer. They had found that 34.9% 
of the patients had a biothesiometer value of more than 25 Volts. The reason for  this 
difference could be because of the difference in the method of application. They had 
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applied the biothesiometer over the plantar aspect of the great toe, while we had applied it 
over the dorsum of the great toe. They had also included patients with ulcers, however we 
had excluded them. Another reason could be that their sample size was 1044 patients, 
much higher than our sample size of 48 patients.(32) 
In our study, among patients with clinical neuropathy, 45% had abnormal NCS and 
among patients without clinical neuropathy, 18% had abnormal NCS. Among patients 
with abnormal nerve conduction studies, 64% of patients had clinical neuropathy. 
According to NCS as gold standard, MNSI has a sensitivity of 64.3%, specificity of 
67.6%, positive predictive value of 45% and Negative predictive value of 82.1%. Another 
study done by Turkaan mete et al had similar results where, among patients with clinical 
neuropathy, 58.8% had abnormal NCS(68). 
 Many studies use  NCS as the gold standard and have validated all tools based on 
NCS.(4,12–14)However there have been suggestions that  NCS alone is not enough for 
the diagnosis of Diabetic peripheral neuropathy, it should be supplemented by clinical 
evidence. (48) 
Even, MNSI, a clinical tool alone is not sufficient to diagnose Diabetic peripheral 
neuropathy. However, Turkan Mete et al showed that NCS had a sensitivity of 55% and a 
specificity of 58% when compared to MNSI and the positive and negative predictive 
values were 38% and 73% respectively(67). In our study NCS was found to have a 
slightly lower sensitivity of 45% and a better specificity of 82.1%. The reason for this 
could again be, as mentioned above, the fact that they had taken 2.5 as cut off for MNSI, 
so their percentage of patients with clinical neuropathy was lower and hence the 
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percentage of patients with abnormal NCS among them are also lesser than ours. The 
reason for the low sensitivity of NCS as compared to MNSI could be that small fiber 
neuropathy is generally not diagnosed by nerve conduction studies and needs other tools 
like thermal testing. (29) 
Fateh et al compared UK Screening Test and MNSI with electrodiagnosis and found that 
according to MNSI, 69% of the patients had clinical neuropathy. The sensitivity for 
MNSI was 75.21% and specificity was 33.3%.(66) Herman et al showed that MNSI had a 
sensitivity of 61% and a specificity of 79% with a cut off of >2.5 of the examination 
score; with respect to clinical examination by a neurologist and NCV with >/= 2 
parameters affected of all the upper and lower limb conventional nerves tested. The 
sensitivity is almost the same, however our study had a slightly lower specificity, the 
reason for this could be the cut off taken as >2.5, while our cut off was 2.(71) As 
previously mentioned, studies have shown that higher the cut off, higher is the specificity. 
(20) 
A study by Muntean et al, published in 2016 February, studied the efficiency of MNSI 
and NCV in the early diagnosis of peripheral neuropathy. The prevalence according to 
MNSI was 50.98% which was similar to our finding of 56.25%.(72) In this study they 
have done Nerve Conduction studies for all patients, however they have not used a single 
criteria which defines whether the NCS is normal or not. They have compared the NCS 
of patients and controls and found a significant difference in certain parameters. For 
MNSI questionnaire,the prevalence of diabetic peripheral neuropathy was 3.92% when 
keeping the old threshold(>/=7), and 23.52% when using the modified 
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threshold(>/=4)(72). In our study, the maximum MNSI history score was 5. Hence there 
were no patients with score of 7 or more. The prevalence increased from 0% to 22.91% 
when the cut off was changed to >/=4. This finding is similar to the above mentioned 
study.  
Gefarri et al showed that the prevalence of diabetic peripheral neuropathy based on 
MNSI was 45%. Out of this 81.7% had symptoms, however only 7.4% met the 
questionnaire criteria for neuropathy based on MNSI ( history score of >/=7).(30) 
 
In the current study, of the total 28 patients without clinical evidence of neuropathy, 
biothesiometer has identified 10 patients (35.71%) to have evidence of large fibre 
neuropathy, and in the group with clinical evidence of neuropathy 17 patients(85%) were 
identified to have neuropathy based on biothesiometry;  by taking the cut off for 
definition of abnormal as 15 V.  In the clinically silent group, 23 patients out of 28 have a 
normal NCS. Of these 23, 6 patients are picked up as abnormal by biothesiometer. Of the 
5 patients who have an abnormal NCS, 4 of them are picked up by biothesiometer. Of the 
20 patients in the group with clinical neuropathy, 9 patients have an abnormal NCS, and 
of these 7 are picked up as abnormal by biothesiometry. Ten out of the eleven patients 
with a normal NCS in the clinical neuropathy group, have an abnormal biothesiometry. 
What is evident here is that there are more number of patients picked up by 
biothesiometry than by NCS; and this number is higher in the group with clinical 
neuropathy (90.9%) than in the group without clinical neuropathy(26%).This shows that 
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biothesiometry correlates more closely with clinical neuropathy than Nerve conduction 
studies.  
It is also observed here that 80-85% of the patients with a normal NCS and an abnormal 
biothesiometer value belong to the mild neuropathy category by biothesiometry(15-25V). 
This also shows that more number of patients with mild neuropathy diagnosed by 
biothesiometry are being missed by nerve conduction studies. It could also mean that 
these are false positive cases and actually don't have neuropathy because nerve 
conduction studies are normal. Here arises the question as to which is the gold standard. 
There are no studies so far which have directly compared Nerve conduction studies and 
biothesiometer. Some consider biothesiometer as the gold standard(32,73) while others 
consider nerve conduction studies as the gold standard.(33,66,69,70) According to other 
authors, even nerve conduction studies alone are not sufficient; there must be clinical 
evidence and electrophysiological evidence to diagnose diabetic neuropathy(48). Ideally 
patients have to be followed up over years to see if they develop ulcers and the 
development of ulcer has to be taken as the gold standard. However, since ours is a cross 
sectional design, we have taken nerve conduction studies alone as gold standard, because 
it is purely an objective test and keeping the general consensus of majority of the studies. 
We have used the AAN criteria to define a case of neuropathy based on NCS. We have 
compared every other screening tool with NCS to determine their sensitivity and 
specificity.  
After diagnosis of any condition, the next step would be management and prevention of 
complications. After diagnosis of diabetic neuropathy, management mainly comprises 
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prevention of complications like ulceration, gangrene and amputation. Medications need 
to be given only in the clinically symptomatic group. Strategies to prevent foot ulceration 
include foot care practices. Since the intervention after diagnosis is mainly knowledge 
and practice of foot care, the ultimate aim would be to pick up maximum number of 
cases, rather than strictly identify who is diseased and who is not. In fact, every patient 
with Diabetes mellitus, irrespective of whether he has neuropathy or not has to be taught 
foot care practices.  
Biothesiometry with a cut off of 15V has a sensitivity of 78.6% and specificity of 52.9%. 
However if we increase the cut off to 25V the sensitivity decreases to 50% and the 
specificity increases to 91.2%.  
A study on evaluation of clinical tools in diabetic peripheral neuropathy by Pouharmidi et 
al showed that the sensitivity and specificity of biothesiometry with a cut off of 24.5V 
was 82% and 70% respectively. The reason for this increased sensitivity could be the fact 
that they had a more strict criteria to define cases with peripheral neuropathy; that is 
clinical neuropathy by NDS (Neuropathy Disability score) and electrophysiological 
evidence of neuropathy.  This study had also taken into consideration another aspect, 
small fiber neuropathy and had defined cases based on clinical evidence and thermal 
perception threshold. For small fiber neuropathy, the sensitivity and specificity of 
biothesiometer was 67% and 46% respectively despite taking the cut off as 20V(29). The 
reason for this is the vibration sense is a measure of large fiber function. This aspect was 
not looked at in our study.  
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Armstong et al showed that biothesiometry with a cut off of 15V had a sensitivity and 
specificity of 90% and 65% respectively. When the cut off value was increased to 25V 
the specificity increased to 85% whereas the sensitivity decreased slightly (85%)(31). 
These values are almost similar to our study, however, the slightly higher sensitivity and 
specificity in this study could be again due to the stricter criteria for defining cases, that is 
any patients with ulcers or history of ulceration.  A study done by Mythili et al had shown 
that biothesiometry had a sensitivity and specificity of 86% and 76% respectively when 
NCS was taken as the gold standard(74).  
Of the total sample size of 48 patients, only 4 (8.3%) of them had an abnormality in 
Semmes Weinstein monofilament testing. All the four patients belonged to the group 
with clinical neuropathy. The sensitivity and specificity of a 2 gram monofilament are 
14.3% and 95.1% respectively; based on nerve conduction studies. The positive and 
negative predictive values are 50% and 72.7% respectively.  
Pourhamidi et al, showed that the sensitivity and specificity of 10 gram monofilament 
was 6% and 97%. This was similar to our study. However they had not used 2 gram or 4 
gram monofilaments. The gold standard used in this study was nerve conduction studies 
and clinical signs together(29).  
A study done by Gill et al in PGI, UP, showed that that only 6.1% of the patients had an 
abnormality in 10 gram monofilament. However, in the same population Biothesiometer 
picked up 43% with 9 V as cut off. This finding was also similar to our study. 
Jayaprakash et al showed that the sensitivity and specificity of 10 gram monofilament 
were  63% and 93% respectively with Vibration proprioception threshold according to 
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biothesiometry as gold standard while Armstrong et al with the gold standard as presence 
or absence of ulcer showed that the sensitivity and specificity for 10 gram monofilament 
with four points of testing were 90% and 85% respectively. Gefarri et al showed that the 
sensitivity and specificity were 69.7% and 87.9% respectively with MNSI as gold 
standard. Arshad and Alvi et al showed a sensitivity of 41.8% and specificity of 92.91% 
with VPT as gold standard.  
There is wide variability among the sensitivity and specificity of 10 gram monofilament 
in different studies. The reason for this could be the fact that there is no standardization 
for the use of monofilament, that is, number of sites to be tested, the location of the sites, 
plantar or distal, the gold standard test used to compare and derive the sensitivity and 
specificity is variable among all these studies, hence it is very difficult to make a 
comparison. Other drawbacks could include lack of blinding, the test itself is a subjective 
one, the sole thickness varies from one ethnic population to another. Other factors 
influencing this are environmental factors such as effect of humidity, temperature, 
filament ageing and filament durability.    
It is observed from the above quoted articles, that when the main outcome measure is the 
presence or absence of ulcer and this is taken as the gold standard, then the sensitivity 
and specificity is much higher. This implies that in advanced cases it is a good tool, 
however for newly diagnosed patients, or those with mild neuropathy it is not a very 
sensitive tool.  
Studies where 10 gram monofilament has a very low sensitivity have suggested the use of 
a lesser calibre monofilament for earlier diagnosis. Studies have recommended that the 
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use of 20 different monofilaments is a more sensitive technique in picking up neuropathy 
earlier(75). However our study has shown that even 2 gram monofilament has a very low 
sensitivity and specificity.  
In our study, we tried to analyze one more derived ratio from the nerve conduction 
studies, the sural radial amplitude ratio. Out of the total 48 patients, 85.42% of the 
patients had an abnormal sural radial amplitude ratio.  Of the total patients with SRAR 
abnormality, 43% had clinical neuropathy and 56.09%  didn't have clinical evidence of 
neuropathy. It was also observed that every patient with an abnormal NCS, also had an 
abnormal SRAR. Among those with a normal NCS also, 80% of the patients had an 
abnormal SRAR. Hence the sensitivity was 100% and the specificity was 91.2%; the 
positive and negative predictive values were 50% and 72.7% respectively.  
Another parameter in nerve conduction studies useful in subclinical diagnosis of 
peripheral neuropathy is F wave. There was a good correlation between the conventional 
NCS and F waves with a p value of 0.003. Among the 14 patients with abnormal nerve 
conduction studies, 11 of them (78.57%) also had an abnormal F wave. Among the 34 
patients with a normal NCS, 11 of them (32.25%) had an abnormal F wave.  
We also found that by combining various screening tools there was a better specificity 
with only a slight decrease in sensitivity. The study with the highest sensitivity was Sural 
radial amplitude ratio(100%). Biothesiometer with a cut off of 25V had a high specificity 
of 91.2%, hence any patient with a biothesiometer value of more than 25V could be said 
to have neuropathy and does not need further investigation. However, on combining this 
with SRAR the specificity increases to 97%.  
101 
 
If a patient has a biothesiometry value of 15 to 25V, performing an additional SRAR 
would help. If SRAR is negative, we can be sure that he is not diseased. If SRAR is 
positive, there is an increase in specificity to 61.8%.  Adding F wave to this combination 
would further increase the specificity to 91.2%.   
If a patient has a normal biothesiometry value of less than 15V, then SRAR can be 
performed. If SRAR is normal then we can be sure that there is no neuropathy. However, 
if SRAR is positive, then the specificity is only 20%, hence an additional F wave is 
needed. If F wave is also positive then the specificity is 82.4%. If F wave is negative, 
then we need to perform the full NCS to be sure whether he has neuropathy or not.  
Although Michigan Neuropathy Screening Instrument has an individual sensitivity and 
specificity of 64.3% and 67.6%, combining it with other screening tools does not increase 
the specificity much, however decreases the sensitivity.  
Pourhamidi et al showed that combining with skin biopsy with biothesiometry, with 
either of the two positive as diseased led to identification of more cases. However adding 
tuning fork or Semmes Weinstein monofilament did not add to the sensitivity. (29) 
Perkins et al showed that by combining the neuropathy score ( 4 query verbal symptom 
assessment), Semmes Weinstein monofilament and biothesiometry, there was an increase 
in the specificity to 89.4% and a decrease in the specificity to 86.7%. (33) 
In our study the total prevalence of diabetic neuropathy based on nerve conduction 
studies was 29.1%, considering the AAN criteria where any two attributes of any two 
nerves, one being the sural nerve, had to be affected to define the patient to have Diabetic 
peripheral neuropathy. However, if we consider the individual parameters, the most 
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commonly affected parameters were Common peroneal nerve conduction velocity and 
amplitude (37.5% and 33.33%), followed by superficial peroneal nerve conduction 
velocity and amplitude ( 33.33% and 29.1% respectively). This is followed by sural nerve 
abnormalities in amplitude and conduction velocities(27% and 20.8%). Tibial nerve 
conduction velocity was abnormal in 12.5% of the patients and amplitude in 16.6% of the 
patients.  A retrospective study done in 63799 electrophysiological counters showed that 
common peroneal nerve amplitudes were abnormal in 32.5% of the patients which was 
similar to our study. However they found 62.7% of the patients with a sural nerve 
abnormality.(76) 
The upper limb motor and sensory nerves were much less affected when compared to 
lower limb nerves. This could be explained by the length dependent peripheral 
neuropathy in diabetes mellitus. The sensory sural and superficial peroneal nerve 
parameters were more affected than the radial or median nerve parameters. This finding 
was similar to a study done by Aruna et al in Telangana, India, published recently, in 
June 2016.(77) This study was done in 30 diabetic and 30 non diabetic patients and they 
also showed that tibial nerve was least affected among lower limb nerves, also similar to 
our study. This study has also shown that sensory nerves of lower limbs are more affected 
than the motor nerves. This is different from our finding where the most common 
abnormality was in the common peroneal motor conduction velocity and amplitude, 
slightly higher than the sural and superficial peroneal parameters.  The fact to be noted 
here is that even though the number of patients with common peroneal nerve 
abnormalities is higher, when we look at the severity of the nerve involvement, there are 
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no patients with an absent common peroneal  CMAPs, they only have a decreased 
amplitude or conduction velocity or both. However, even though only 29.16% of patients 
have abnormal sural NCS, 20% have absent SNAPs. Abnormal superficial peroneal 
SNAPs are found in 37.5% of the patients, and 33.33% of them have absent SNAPs. This 
indicates that the severity of sensory involvement is higher than that of motor 
involvement. Another study done by Bagchi et al has shown that there is a significant 
difference in both motor as well as sensory nerve parameters, even though it is commonly 
thought that motor nerves are rarely involved. (65)Even among the sensory nerves, it is 
noticed that superficial peroneal is more affected that sural nerve. The AAN criteria(42) 
and other studies say that sural is more affected than superficial peroneal(76). Lo et al has 
shown similar results as ours where superficial peroneal nerve is more affected than the 
sural nerve. They have shown that superficial peroneal nerve was affected in 89% of their 
patients, while sural nerve was affected only in 75% of the patients(78). The reason for 
this high percentage of patients being affected is that they have taken patients who have 
already been diagnosed with peripheral neuropathy. All their patients had parasthesia and 
distal motor and sensory signs and symptoms.    
In our study, the common peroneal motor nerve conduction studies were more affected 
than the tibial NCS, keeping in line with centripetal progression of peripheral neuropathy.  
In our study, the amplitude and conduction velocity have a significant correlation with 
each other for almost all the nerves (p value of <0.001 for sural and superficial peroneal 
nerves, 0.003 for common peroneal nerve, 0.007 for tibial nerve). This is similar to 
another study done by Wilson et al.(79) Amplitude denotes the axonal continuity, 
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whereas conduction velocity denotes the degree of myelination. This shows that axonal 
loss is superimposed by demyelination in diabetic peripheral neuropathy. There could be 
another explanation to this, metabolic abnormalities in diabetes alter the sodium, 
potassium and calcium channels, which would affect the propagation of action potentials 
across the axon.(79) 
Multiple logistic regression analysis was done for the parameters which were significant 
on univariate analysis and showed an increase in risk of diabetic peripheral neuropathy 
with increasing age(OR 1.16, 95% CI 1.04 to 1.29, p=0.007) and severity of diabetes, as 
measured by HbA1C (OR 1.85, 95%CI 1.18 to 2.9, p=0.008). It has been shown that 
even in the normal population, age has a significant influence on nerve conduction 
parameters.(27–29) It has been explained that this could be due to changes in nerve fibre 
membrane, decrease in the number of fibres and a decrease in the nerve fibre diameter, as 
age increases.(45)We had observed that there was increase in the occurrence of diabetic 
neuropathy as the age increased. Even though there is a general change in the nerve 
conduction parameters with increasing age, this difference is more pronounced in those 
with diabetes. Another study done by Gill et al also showed that there was a significant 
correlation with increasing age (OR 1.7, 95% CI: 1.2-2.5, P = 0.002 )(28). Other studies 
also showed significance of age which is similar to our study.(6,7,34,44,65,77,80) Older 
people have to be routinely screened as it is very important to identify neuropathy early. 
They are more prone to ulceration and complications keeping in view the associated 
visual and vascular problems. 
In our study, we have identified that the severity of diabetes based on HbA1C also had a 
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significant correlation with the occurrence of neuropathy. This was similar to some 
studies(7), however some other studies have said that this was not a significant 
correlation. (28) 
Our study showed that the duration of diabetes doesn't significantly affect the presence or 
absence of neuropathy based on NCS. This was similar to a study done by Aruna et al. 
(77) However, some studies have shown that the duration of diabetes has a significant 
association with the occurrence of diabetic neuropathy. (6,7,80,81) This could be because 
duration of diabetes is not a reliable parameter as we don't know the actual duration of 
diabetes prior to the diagnosis. It would be more relevant to consider the duration of 
symptoms prior to the diagnosis of Diabetes mellitus. Some studies have shown that the 
duration of symptoms prior to diagnosis of diabetes caused an increased risk for diabetic 
neuropathy.(28) Another study, done by Novella et al showed that in patients with 
idiopathic sensory neuropathy there was a significant percentage with undiagnosed 
diabetes mellitus and impaired glucose tolerance.(82)However, in our study, we have not 
taken into account the duration of symptoms prior to the diagnosis of diabetes, and this 
would be a potential limitation. Other parameters like gender and BMI didn't correlate 
with the occurrence of neuropathy.  
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LIMITATIONS: 
1. This was a pilot study and the sample size was small. More number of patients are 
needed to get a more accurate sensitivity and specificity of the various screening tools.  
2.  NCS is considered as the gold standard for the diagnosis of neuropathy. However 
some studies have quoted that NCS alone is not sufficient to diagnose peripheral 
neuropathy. The ideal gold standard would be development of ulcers. Hence it would 
have been good to follow up the patients with both NCS normal and abnormal findings 
and see which group develops more ulcers. By this the sensitivity and specificity of the 
various screening tools could be assessed. However, ours is a cross sectional 
observational study and we have not followed up patients.  
3. Alcoholic patients were not excluded from the study and it could have been a 
confounding factor.  
4. Duration of symptoms prior to the diagnosis of diabetes could have been looked into as 
it would be more relevant than the time since diagnosis.  
5. Normal NCS is affected significantly by age and height. This was not taken into 
consideration. It would be more appropriate to take age and height corrected values of 
NCS while interpreting abnormal data.  
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CONCLUSIONS: 
 
The following conclusions were drawn from the study:  
1. Twenty nine percent of the patients with diabetes mellitus, without foot ulcers, were 
diagnosed to have peripheral neuropathy based on nerve conduction studies, 56.25% 
based on biothesiometer with 15V as cut off, 41.66% based on MNSI and 8.3% based on 
Semmes Weinstein monofilament testing.  
2. There was a significant relation of MNSI with Nerve conduction studies (p=0.041), 
Semmes Weinstein monofilament testing (p=0.013) and biothesiometry (p=0.001). The 
agreement between MNSI and NCS was 66.67%   
3. Of the patients with a normal nerve conduction study, 94.11% were found to have 
either no neuropathy or mild neuropathy according to biothesiometry. Of the 14 patients 
with abnormal  NCS, 11(78.57%) could be picked up by biothesiometry. The relation 
between the results of NCS and biothesiometry was statistically significant in the group 
without clinical neuropathy (p value 0.023). The agreement between biothesiometer and 
NCS is 79.17%.  
4. There was a statistically significant relation between neuropathy diagnosed by SRAR 
and by conventional NCS (0.07). Significant results were also noticed in the relation 
between neuropathy picked up by minimal F wave latency and conventional NCS 
(0.003). There was also a significant relation between the mean minimal F wave latencies 
of all nerves and biothesiometry. This shows that SRAR and minimal F wave latency are 
useful tools in diagnosing diabetic peripheral neuropathy.  
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5. The sensitivity and specificity of biothesiometer with a cut off of 25V was 50% and 
91.2% respectively and when the cut off is reduced to 15V, the sensitivity increases to 
78%, while specificity decreases to 52.9% with reference to NCS. The sensitivity and 
specificity of MNSI was 64.3% and 67.6% respectively. SRAR had the highest 
sensitivity of 100%, but a low specificity of 20% based on NCS as gold standard.  
It may be concluded that if a patient has a biothesiometry value of more than 25V, no 
further testing is required as the specificity is 91.2%. If the biothesiometry value is 15 to 
25V, performing an additional SRAR would help. If SRAR is negative, we can be sure 
that he is not diseased. If SRAR is positive, there is an increase in specificity to 61.8%.  
Adding F wave to this combination would further increase the specificity to 91.2%.   
If a patient has a normal biothesiometry value of less than 15V, then SRAR can be 
performed. If SRAR is negative, we can be sure that he is not diseased. If SRAR is 
positive, then an additional F wave is needed. If F wave is also positive then the 
specificity is 82.4%. If F wave is negative, then we need to perform the full NCS to be 
sure whether he has neuropathy or not.  
SRAR and biothesiometry are quick to perform. F wave study requires relatively longer 
time and expertise, however is less time consuming than the entire NCS.  
Though NCS is considered the gold standard for diagnosis of diabetic peripheral 
neuropathy, it is cumbersome, time consuming, needs expertise and is painful to the 
patient although non invasive.  Hence this study has shown that by combining 
biothesiometry, SRAR and F wave studies, the need for conventional NCS can be limited 
to selected cases.  
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ANNEXURE 1: THESIS DATA(48 patients): 
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ANNEXURE 3: PATIENT INFORMATION SHEET: 
A study is being done to correlate the clinical methods and nerve conduction 
studies in early diagnosis of diabetic peripheral neuropathy. You are being invited 
to participate in this research study. Before you make a decision, we would like to 
provide certain details about the research which are essential for you to know.  
1. WHAT IS THE PURPOSE OF THIS STUDY? 
Diabetes is a worldwide problem and is very common in our country. It is a condition 
wherein the blood sugar levels are high. As the duration of disease increases, it is known 
to produce various complications, that is, it can affect the eyes, kidneys, heart, nerves etc. 
When it affects the nerves, we get a condition called diabetic neuropathy. This is an 
important complication and patients need to be aware of it because it can eventually lead 
to foot ulcers, amputation (removal of a part of the body), gangrene and even death. The 
aim of this study is to study the various clinical methods and nerve conduction studies in 
early detection of diabetic neuropathy. Every patient who is diagnosed with Diabetes 
mellitus will be given a questionnaire to enquire about the symptoms of neuropathy. Then 
a quick clinical examination will be done. Then the sense of vibration will be tested using 
a biothesiometer (a hand held vibrating instrument which will be placed at the tip of great 
toe of the patient). Then they will all be subjected to nerve conduction studies (a test used 
to evaluate the function of nerves and speed at which the nerve conducts). After that, a 
comparison of all these tests will be done to see which picks up the disease earlier and 
helps in early detection.  
2. WHO WILL PERFORM THE TEST?   WHAT ARE THE POSSIBLE COMPLICATIONS? 
The examination and the nerve conduction studies will be performed by the 
principle investigator. There is no problem in performing this test. The 
investigation will not adversely affect my health in any forseeable manner. There 
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may be a small tolerable pain while performing this test. But it usually resolves 
within minutes of completion of the study. 
3. WILL WITHDRAWL OR NON PARTICIPATION AFFECT THE USUAL TREATMENT? 
The patient can withdraw from the study at any point of time without being obliged 
to give a reason. He is also free to decide regarding his participation. Non-
participation or withdrawal will not affect his usual treatment at any point of time 
as an out-patient or an in-patient.  
4. DO I HAVE TO PAY FOR THE INVESTIGATIONS? 
You will not have to pay for the nerve conduction studies being done as a part of 
the research.  
5. WILL MY TEST REPORTS BE KEPT CONFIDENTIAL? 
The results of the study will be published in a medical journal but you will not be 
identified by any name in any public presentation of results. However your medical 
notes may be reviewed by people associated with the study, without any additional 
permission, should you decide to participate in the study. 
For any further questions, contact: Dr. Saraswathi Ramanathan- 09791102971 
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ANNEXURE 4: INFORMED CONSENT FORM TO PARTICIPATE IN A 
RESEARCH STUDY  
Study Title: CO-RELATION OF CLINICAL TESTING AND NERVE CONDUCTION 
STUDIES IN DIABETIC PERIPHERAL NEUROPATHY 
Study Number: ____________ 
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
(Subject) 
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions. [  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [  ] 
(iii)  I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look 
at my health records both in respect of the current study and any further research that may 
be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
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Signature or thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name & Address of the Witness: ______________________________ 
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ANNEXURE 5: PROFORMA FOR DATA COLLECTION 
 
 
Patient Details: 
 
Name of the patient – 
 
Age (years)–                 Sex – Male / Female 
 
Occupation – 
 
Education – 
 
Address – 
 
Hospital no. – 
 
Contact no. – 
 
Presenting complaints : 
 
 
 
History of Diabetes Mellitus- 
 
Year of diagnosis/ age at onset – 
 
Type of Diabetes – 
 
Initial presenting symptoms- 
 
Initial GRBS/AC/PC – 
 
Treatment history-   Insulin –  
                OAD - 
                Current treatment regime - 
 
Foot History 
 
    Vascular symptoms 
 
Claudication – Y/ N 
Rest pain – Y/ N 
Non healing ulcer – Y/ N 
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    Footwear   
Type of  footwear  MCR – Y/ N 
                Normal – Y/ N 
 
Barefoot walking- Y/N 
Walking hours per day 
Standing hours per day 
 
 
Complications of Diabetes Mellitus : 
 
Diabetic Retinopathy 
Yes [  ] 
No [  ] 
 
 
Diabetic Nephropathy 
Yes [  ] 
No [  ] 
 
Diabetic Neuropathy 
Yes [  ] 
No [  ] 
 
Cardiovascular disease 
Yes [  ] 
No [  ] 
 
Cerebrovascular disease 
Yes [  ] 
No [  ] 
 
Peripheral vascular disease 
Yes [  ] 
No [  ] 
 
 
Past History: 
 
Diabetes mellitus 
 
Hypertension 
 
 
Foot ulcer 
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Tia / stroke 
 
 
Others  
 
Personal History : 
 
  Smoking – 
 
  Alcohol consumption -  
 
Height – 
 
Weight – 
 
Body Mass Index – 
 
 
SYSTEMIC EXAMINATION 
 
Respiratory system – 
 
Cardiovascular system – 
 
Abdomen – 
 
Central nervous system –  
 
 
INVESTIGATIONS – 
 
Hemoglogin – 
 
Glycoylated haemoglobin – 
 
Serum fasting Lipid profile – 
 
Serum Creatinine – 
 
Urine Microalbumin –  
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ANNEXURE 6: MICHIGAN NEUROPATHY SCREENING INSTRUMENT 
A. History (To be completed by the person with diabetes) 
Please take a few minutes to answer the following questions about the feeling in your legs 
and feet. Check yes or no based on how you usually feel. Thank you. 
1. Are you legs and/or feet numb? Yes No 
2. Do you ever have any burning pain in your legs and/or feet? Yes No 
3. Are your feet too sensitive to touch? Yes No 
4. Do you get muscle cramps in your legs and/or feet? Yes No 
5. Do you ever have any prickling feelings in your legs or feet? Yes No 
6. Does it hurt when the bed covers touch your skin? Yes No 
7. When you get into the tub or shower, are you able to tell the 
hot water from the cold water? Yes No 
8. Have you ever had an open sore on your foot? Yes No 
9. Has your doctor ever told you that you have diabetic neuropathy? Yes No 
10. Do you feel weak all over most of the time? Yes No 
11. Are your symptoms worse at night? Yes No 
12. Do your legs hurt when you walk? Yes No 
13. Are you able to sense your feet when you walk? Yes No 
14. Is the skin on your feet so dry that it cracks open? Yes No 
15. Have you ever had an amputation? Yes No 
Total: 
MNSI, © University of Michigan, 2000 
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ANNEXURE 7: NERVE CONDUCTION STUDIES METHODOLOGY: 
 
Sural sensory nerve conduction: 
The active electrode was placed between the lateral malleolus and the tendoachilles. The 
reference electrode was placed 3cm distal to the active electrode. The ground was placed 
between the recording and the stimulating electrodes. Stimulation was done at the 
posterior midline of the leg just beneath the prominence of gastrosoleus, anode was 3 cms 
proximal to the cathode.  
 
Superficial peroneal sensory nerve conduction: 
The active electrode was placed over the dorsum of the foot at the level of the malleoli, 
slightly lateral to the midline. Reference electrode was placed 3cms distal to the active 
electrode. Ground was placed at the distal dorsum of leg between the recording and the 
stimulating electrodes. Stimulation was done over the distal anterolateral leg around 10-
14cms proximal to the lateral malleolus. Anode was 3cms proximal to the cathode.  
 
Tibial nerve conduction: 
The active electrode was placed over the belly of the abductor hallucis on the medial 
aspect of the foot, just beneath the navicular bone. The reference electrode was placed 
3cms distal to the active electrode, over the tendon of the abductor hallucis. Ground 
electrode was placed over the dorsum of the foot between the active and reference 
electrodes. Stimulation at the ankle was done posterior to the medial malleolus with the 
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anode 3cms proximal to the cathodeStimulation at the knee was done in the popliteal 
fossa, one to two finger breadths medial to the biceps femoris tendon. 
 
Common peroneal nerve conduction: 
The active electrode was placed over the dorsum of the footover the belly of the EDB 
muscle. The reference electrode was placed 3cms distal to the active electrode over the 
tendon of the EDB. Ground was placed on the dorsum of the foot between the active and 
reference electrode. Distal stimulation was done over the anterior ankle with anode 3cms 
distal to the cathode. Proximal stimulation was done just below the head of fibula and in 
the lateral aspect of the popliteal fossa.  
 
Median Sensory nerve conduction: 
This was done using ring electrodes. The active electrode was placed around the mid-
portion of the proximal phalynx of the second digit (just proximal to the proximal 
interphalyngeal joint). Reference electrode was placed 3cms distal to the active electrode. 
Ground was placed on the dorsum of the hand between the active and the reference 
electrodes. Stimulation was done over the median nerve between the FCR(Flexor carpii 
radialis) and the palmaris longus, around 14cms proximal to the recording electrode. 
Anode was 3cms proximal to the cathode. 
 
Radial Sensory nerve conduction: This was  done using disc electrodes. The active 
electrode was placed over the anatomical snuff box formed by the extensor pollicis brevis 
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and the abductor pollicis longus tendons laterally and extensor pollicis longus tendon 
medially. The reference electrode was placed 3cms distal to the active electrode. Ground 
electrode was placed over the dorsum of the hand between the recording and stimulating 
electrodes. Stimulation was done over the dorsolateral edge of the radius bone, 10cms 
from the active recording electrode with the anode 3cms proximal to the cathode.   
 
Median Motor nerve conduction: 
The active electrode was placed over the belly of the abductor pollicis brevis (APB)  
muscle and the reference electrode was placed 3cms proximal to the active electrode, 
over the tendon of the APB muscle, at the base of the proximal phalynx of the thumb. .  
Ground electrode was placed on the dorsum of the hand between te active and the 
reference electrodes. Stimulation at the wrist was done 2-3 cms proximal to the distal 
crease between the FCR and Palmaris longus. At the elbow, stimulation was done at the 
antecubital fossa over the brachial artery, medial to the biceps tendon. At the arm, 
stimulation was done at the upper arm, just below the belly of the biceps. Anode was 
proximal to the cathode.  
 
Ulnar motor nerve conduction studies: 
The active electrode was placed over the belly of the ADM (abductor digiti minimi) and 
the reference electrode was placed over the tendon of ADM at the base of the proximal 
phalynx of little finger. Ground is placed on the dorsum of the hand, between the 
recording and stimulating electrodes. Stimulation at the wrist was done 2-3cms proximal 
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to the distal crease, just lateral to the flexor carpi ulnaris (FCU) tendon with the anode 
3cm proximal to the cathode. Below elbow stimulation was done with the cathode 3-
4cms distal to the medial epicondyle and retrocondylar groove. Above elbow stimulation 
was done at 4-5cms proximal to the medial epicondyle and retrocondylar groove between 
the biceps and the triceps. with the anode 3cms proximal to the cathode.  
.   
